The Monoterpenoid Perillyl Alcohol: Anticancer Agent and Medium to Overcome Biological Barriers.

1. Introduction

The blood–brain barrier (BBB) is a highly selective semipermeable interface between the bloodstream and the brain parenchyma that acts as a gatekeeper to control the entry of substances from the systemic circulation into the brain. It not only manages the brain entry of endogenous substances present in the circulation, such as neuroactive solutes, nutrients, hormones, and antibodies, but also provides protection by restricting brain access by potentially harmful agents, such as metals and toxins. The influx and efflux of molecules are actively regulated with the prime objective to maintain brain homeostasis and protect this organ from harm [ 1 , 2 ]. For a detailed description of these mechanisms and their underlying anatomical elements, the interested reader is referred to excellent recent reviews [ 3 , 4 ].

By allowing necessary nutrients and other beneficial materials to enter the brain whilst allowing waste products to exit and preventing harmful substances from entering the brain, the BBB provides great benefit in protecting and ensuring optimal brain function. At the same time, however, this armor-like role of the BBB represents a double-edged sword because it can also block brain access by a large number of pharmacological agents that may be needed within the brain in order to effect their therapeutic action against brain-localized diseases. In fact, within the context of brain-metastatic spread from peripheral tumors of the lung, breast, melanoma, and some others, effective exclusion of therapeutic agents from the brain has resulted in the well-recognized paradox of an increasing incidence of brain metastases despite improvements in general clinical care and substantial progress in developing novel therapeutic agents [ 5 , 6 , 7 ]. For example, in the case of breast cancer subtypes that overexpress epidermal growth factor receptor 2 (EGFR2/HER2/Neu; generally called HER2+), the introduction of the humanized monoclonal antibody trastuzumab (Herceptin ® ) and other HER2-targeted agents resulted in significantly improved treatment outcomes for the peripheral disease. However, HER2+ breast cancer has a propensity to metastasize to the brain and these brain seeds cannot effectively be reached by therapeutic antibodies. As a result, while extracranial malignancy generally responds well to intravenous trastuzumab (and other HER2-targeted therapeutics), cancerous seeds in the brain are, for the most part, isolated from this systemic therapeutic intervention. Whilst treatment success in the periphery enables patients to live longer, cancer cells residing in the sanctuary of the brain consequently have more time to develop sizable metastases and eventually trigger cancer recurrence and a grim prognosis [ 5 , 6 , 7 , 8 ].

Secondary brain cancer as a result of metastatic spread from peripheral cancer types represents the most frequent intracranial malignancy. Primary brain cancers, malignant gliomas in particular, present with no better prognosis and their effective management also remains an inadequately met clinical need. For instance, glioblastoma (GBM, formerly known as glioblastoma multiforme; IDH wildtype, grade IV) is the most aggressive cancer that originates in the brain, with a median overall survival of 8–10 months from the time of diagnosis [ 9 , 10 , 11 ]. Patients with higher performance scores (based on functional impairment [ 12 ]) and overall greater physical robustness at the time of diagnosis are better predisposed to withstand the rigors of extensive and taxing therapies and, therefore, are more likely to experience an extended average survival of another 6–12 months. However, even with patients demonstrating higher Karnofsky performance scores (KPS), recurrence of GBM is nearly universal and the vast majority of patients eventually die from this insidious disease within just a few years at best.

The current standard of care for GBM consists of surgery (if possible), followed by chemoradiation, which consists of oral temozolomide (TMZ; Temodar ® ) combined with ionizing radiation. TMZ is a prodrug that releases diazomethane, which is an alkylating agent. The clinical use of TMZ for GBM was cemented by a landmark clinical study by Stupp et al. [ 13 ], showing that the combination of radiation therapy (RT) with TMZ for 6 weeks, followed by 6 months of TMZ alone, resulted in greater patient survival duration than was achieved by the use of radiation alone. It was, however, noted that the median survival benefit was small: inclusion of TMZ with the RT regime extended the average survival from 12.1 months (RT alone) to 14.6 months, i.e., a life expectancy increase of only 2.5 months. The fraction of patients surviving 5 years also showed an increase, from 1.9% for RT alone to 10.9% for the combination treatment [ 13 , 14 ]. While these improvements were validated by subsequent studies, it remains noteworthy that clinical trials generally harbor selection bias, usually favoring patients with higher performance scores and, therefore, patients in ordinary clinical practice may not always be able to receive or tolerate the full spectrum of therapeutic interventions. As such, the publicized survival data derived from most clinical trials represent a somewhat skewed picture as compared to the entire cohort of GBM patients, and improved therapies are still urgently needed [ 15 ].

Similar to the above example of trastuzumab, where the BBB severely limits access of this therapeutic antibody to its intracranial HER2+ targets, the BBB significantly interferes with TMZ brain entry as well. Although TMZ is generally considered BBB permeable, neuropharmacokinetic measurements in patients with primary or metastatic brain tumors established a brain-to-plasma TMZ concentration ratio of only 0.2 [ 16 , 17 ], indicating that in practice, only a small fraction of systemically available TMZ enters the brain. This low amount entering the brain is not entirely surprising because TMZ was not specifically developed as a brain-targeting agent.

Within malignant brain lesions, the organization and function of the BBB can be altered due to pathological changes caused by tumor cells, including extensive neo-angiogenesis, which is particularly prominent in GBM tissue. Such structural alterations are generally referred to as the blood–tumor barrier (BTB), which is located between brain tumor tissue and adjacent capillary vessels [ 18 , 19 ]. It was observed that the barrier function of a BTB is compromised and not as effective as a normal BBB, a phenomenon called leakiness. This may explain why some chemotherapeutic drugs, such as etoposide, cisplatin, methotrexate, or cyclophosphamide, which are known to not effectively penetrate the BBB, can achieve occasional therapeutic responses in the brain when given at higher dosages [ 20 , 21 ]. The severity of barrier breakdown is, however, highly heterogeneous, both in primary and secondary brain malignancies. For example, a detailed preclinical analysis [ 22 ] of 2000 individual lesions of breast–brain metastases in mice demonstrated large differences between individual lesions—and even within the same lesion—with regard to BBB/BTB permeability. Although 90% of these lesions showed barrier compromise, their uptake of different clinically used chemotherapeutic drugs was less than 15% of that of other tissues or peripheral metastases. Clinical studies in GBM patients that used contrast-enhanced magnetic resonance imaging (MRI), positron emission tomography (PET) imaging, and analysis of surgically removed tissues also established significant heterogeneity: while some tumor regions present with deteriorated BTB, others display an intact barrier [ 23 , 24 ]. Therefore, despite being partially compromised within brain tumor lesions, the BTB is still operational enough to substantially impede effective drug delivery and prevent therapeutic activity. Despite the presence of more or less “leaky” sections of the BTB, effective drug delivery requires consideration of the intact BBB for reliable and more broadly applicable therapeutic benefit.

Several diverse strategies are being explored to increase drug penetration of the BBB and achieve efficient brain entry of therapeutic agents. Some of these are highly invasive procedures that may require surgery and hospitalization of patients, such as intrathecal and intraventricular injection, convection-enhanced delivery by direct injection, or implantation of gels, wafers, and microchips for localized release, all of which seek to circumvent the BBB and place therapeutic agents directly into the brain or tumor tissue. Transient opening of the BBB by intracarotid infusion of mannitol or chemical disruptors (e.g., leukotrienes, bradykinins) represents another invasive method that can facilitate brain access for drugs present in the systemic circulation. All of these procedures are, however, associated with significant risks, such as vasogenic brain edema, embolism, seizures, and neurological deficits, as well as high costs [ 19 , 25 , 26 ].

There is a great need then for less invasive procedures that allow for effective drug access to brain-localized malignancies. Among the strategies that are being pursued to achieve this goal are novel interventions that reversibly open the BBB, drug modifications that enable more efficient penetration of the BBB, or intranasal delivery with the goal to achieve direct nose-to-brain drug transport to circumvent the BBB altogether. In the discussion that follows, we review progress in this field that was achieved with the use of perillyl alcohol (POH), a naturally occurring monoterpenoid related to limonene [ 27 ], and with NEO100, an engineered version of this monoterpenoid that features ultra-high purity and is being produced under Current Good Manufacturing Practice (CGMP) regulations. NEO100 has revealed multifaceted applicability and uses that include intranasal delivery (either alone in monotherapy fashion or as a facilitator of enhanced permeability for other drugs), intra-arterial delivery to reversibly open the BBB, and as a covalently attached modifier for other drugs to achieve superior penetration, not only of the BBB but also of other critical barriers, the cell membranes (cytoplasmic and nuclear), and the skin. Below, we provide a detailed description of the physicochemical properties of POH and NEO100, followed by a review of their versatile applications to overcome biological barriers and allow for improved therapeutic access to malignant lesions.

2. The Monoterpenoid Perillyl Alcohol (POH)

2.1. Biochemical Description of POH

POH was first extracted from herbs of the genus Perilla [ 28 ], from which it derived its name, and to various extents is a constituent of essential oils from a variety of botanicals, including peppermint, spearmint, lavender, bergamot, lemongrass, sage, caraway, thyme, rosemary, celery seeds, cherries, and cranberries [ 27 , 29 ]. Common synonyms of POH are perilla alcohol, perillol, and p-mentha-1,8-dien-7-ol, among others. Its IUPAC name is (4-prop-1-en-2-ylcyclohexen-1-yl)methanol. It is a terpene (or, more accurately, a terpenoid, as it is a terpene modified by derivatization through the addition of a hydroxyl group). The terpenes were so-named in 1866 by the German chemist August Kekulé from the name of the pine-oil extract turpentine [ 30 ], which is primarily comprised of terpenes, a classification expanded to include tens of thousands of chemical substances made up of repeating 5-carbon isoprenyl subunits (see Scheme 1 for an overview of some terpene biosynthetic pathways) [ 31 ].

POH itself is a fragrant oil with a somewhat heavy, floral, lavender-like fragrance that is used in perfumes, cosmetics, and some cleaning products. Other reported uses are as an ingredient in baked goods, frozen dairy, gelatine, puddings, beverages, and candies [ 32 ]. It is, however, now also of increasing interest as a therapeutic agent in the prevention and treatment of cancers (details below). POH is a chiral compound (i.e., one whose 3-D shape is not superimposable on its mirror image “enantiomer”). The naturally occurring form of POH is primarily the enantiomer with (S)-stereochemistry at the chiral center (which is the carbon atom having the substituents that are non-superimposable on their mirror image) ( Scheme 1 ). Although the biological activity of the other mirror image (R)-enantiomer is, as yet, untested, most biological components and most biochemical processes involve single enantiomer stereochemistry such that it is likely that different enantiomers will interact differently with biological receptors and pathways. This is evident, for example ( Scheme 1 ), with the terpenoid (R)-carvone (from spearmint oil), which, unsurprisingly, smells of spearmint, whilst its enantiomer (S)-carvone (from caraway or dill seed oil) exhibits the totally different odor of rye bread (which is flavored by caraway seeds) due to the carvones’ stereochemically differentiated interactions with the chiral olfactory receptors in our nasal cavities [ 33 , 34 ].

Scheme 1 shows the biosynthesis and chemical structures of these aforementioned terpenoid materials. Note that the stereochemistry in this reaction scheme (for example illustrated by the limonene enantiomer intermediates in the biosynthesis of POH and carvones) may be designated by (+)/(−), D/L, or (R)/(S), which can be confusing. (R) and (S) are determined from the 3-D chemical structure, where (R) denotes the enantiomer with the hydrogen (H) substituent on the chiral carbon atom oriented to lie backward away from the viewer and the other substituents arranged clockwise in descending order of priority (atomic weight), whilst the (S) enantiomer is the mirror image of the (R) enantiomer. The D designation refers to the stereochemistry derived by chemical synthesis from D-glyceraldehyde and vice versa for L. Meanwhile, the (+) or (−) refer to the direction of rotation of plane-polarized light by a solution of the material where (+) implies clockwise rotation of plane-polarized light and (−) denotes the opposite. Suffice to say that there is no reliable general rule to predict the correlation of (R) vs. (S) with D or L and with (+) or (−) [ 35 ].

POH is classified as a cyclic monoterpenoid (where the monoterpene designation refers to its biosynthesis from a single geranyl pyrophosphate moiety, shown in Scheme 1 , followed by oxidation of the terpene backbone while catalyzed by cytochrome P450 enzyme to achieve the terminal hydroxylation; hence, the designation “terpenoid” rather than “terpene”). Its molecular weight is 152.2 g/mol, which is about 2.5 times the molecular weight of, for example, acetic acid in vinegar; therefore, it is a lot less volatile than acetic acid (boiling point 118–119 °C at atmospheric pressure), with a consequently higher boiling temperature of 244 °C at atmospheric pressure, but it still exerts sufficient vapor pressure and active interaction with our olfactory biochemistry to be easily detected by smell. The polar hydroxyl functionality makes the molecule more hydrophilic (i.e., water miscible) than non-hydroxylated equivalent terpenes, such as pinenes, which are water immiscible, such that POH does demonstrate some limited solubility in water (around 1.9 mg/mL) and a mix of lipophilic (fat solubility) and hydrophilic (water solubility) properties. It is this biphilic (or amphiphilic) nature (both fat and water affinity) that perhaps explains the remarkable properties of POH in achieving essentially free passage throughout the body, across the blood–brain barrier, and across cell membranes to realize its therapeutic potential and to potentiate the therapeutic potential of other materials with which it is partnered.

Whilst nature does an astonishingly efficient job at converting carbon dioxide, water, sunlight, and air to POH via biosynthesis in plants, the POH so generated is present in a cocktail with other products; as such, this POH is unsuitable for pharmaceutical use without costly and extensive purification. This is because regulatory approval for pharmaceutical use requires consistent high-purity composition to verify safety and efficacy, without risk of any changes in composition that could introduce toxicity risks or variation in therapeutic efficacy that may imply potential risks to patients. Industrial manufacturing of POH therefore generally relies upon a combination of biosynthetically produced high-purity, low-cost (-)-beta-pinene, with subsequent industrial manufacturing conversion of this to POH, i.e., utilizing a “semi-synthetic” preparation. An example is outlined in Scheme 2 [ 36 ]. Chemistry along these lines is used for the industrial manufacture of POH at around 95% purity for perfume and antimicrobial purposes. Furthermore, the ability of bacterial enzymes to modify the monoterpene backbone has been exploited for the production of “natural” aromas for the flavor and fragrance industries, where suitably genetically engineered bacterial strains are used as a source of POH and other known and novel monoterpene derivatives [ 37 , 38 , 39 ]. For pharmaceutical use, however, even higher purity and consistency of composition are ideally required so that derivatization of POH is developed to generate a crystalline dinitrobenzoate ester intermediate (which is more easily purifiable by crystallization), followed by hydrolysis to release the purified POH ( Scheme 3 ) [ 40 ]. The POH manufactured in this way was named NEO100 and is undergoing clinical trials for the treatment of glioblastoma (see details in sections below).

2.2. Recognizing POH’s Potential for Anticancer Purposes

The earliest studies that explored the potential of POH for anticancer purposes were spearheaded by the team of Michael Gould, Jill Haag, Pamela Crowell, and others at the University of Wisconsin–Madison in Madison, Wisconsin [ 41 , 42 , 43 ]. Using a rat carcinogenesis model with 7,12-dimethylbenz(a)anthrazene (DMBA)-initiated mammary tumors, it was shown that 2% POH mixed with a daily diet ( w / w ) over 10 weeks resulted in regression of the majority of small and advanced mammary carcinomas [ 43 ]. Of note, the authors compared the activity of POH side by side to that of limonene and observed greater activity of the former, which they ascribed, at least in part, to differences in metabolic pharmacokinetics, where an acute dose of 2% POH achieved 2–3 times higher levels of terpene metabolites (primarily perillic acid and dihydroperillic acid) in the plasma of the treated rats as compared to rats fed 10% limonene. Similarly, when POH and limonene were dosed chronically at the same levels, the terpene metabolites were measured at >10-fold higher plasma levels in the case of POH. In parallel studies that compared the inhibitory activity of POH and limonene on the isoprenylation of small G proteins (details below), it was found that POH was greater than fivefold more potent than limonene [ 42 ]. Therefore, despite numerous earlier reports on the oncotherapeutic properties of limonene [ 44 , 45 , 46 , 47 ], these newer studies favored POH for further development and clinical trials (details below).

2.3. Mechanisms of POH Anticancer Function

The first cellular target of POH to be identified was the process of isoprenylation of small G proteins, where POH and, to a lesser extent, limonene were found to inhibit small G protein isoprenylation, along with restricted cell proliferation [ 41 , 42 , 48 , 49 ]. In particular, the inhibition of farnesylation of p21-Ras generated excitement in view of the recognized critical role of this proto-oncoprotein in cell growth regulation and carcinogenesis [ 50 , 51 , 52 ]. A critical step during the activation process of Ras is its posttranslational modification via farnesylation, providing an anchor for attachment of the protein to the inner leaflet of the cytoplasmic membrane, which is critically required for the protein’s mitogenic and oncogenic activity [ 53 ]. The discovery that this process could be inhibited by POH provided early insight into how this monoterpenoid might interfere with tumor cell growth [ 48 , 51 , 54 ]. Besides Ras, however, numerous additional targets were recognized over the years that followed and it appears that the anticancer function of POH might be derived from its influence over a variety of different targets and processes in cancer cells.

Several studies reported on the ability of POH to restrict the cell cycle progression of tumor cells through its effects on components of the cell cycle machinery. For instance, treatment of cells with POH in vitro results in the downregulation of various cyclin proteins, which represent the regulatory subunits of cyclin-dependent kinases (CDKs) whose activity is essential for cell cycle progression. Conversely, POH stimulates the expression of CDK-inhibitory proteins p15 (INK4b, CDKN2B ), p21 (WAF/Cip1, CDKN1A ), and p27 (Kip1, CDKN1B ), all of which are able to block CDK activity [ 55 , 56 , 57 , 58 ]. The ensuing cell cycle arrest prevents tumor cell proliferation in vitro, translating to the inhibition of tumor growth in vivo.

A host of other cellular targets of POH were identified, including immediate-early genes c-Fos and c-Jun (which heterodimerize to form transcription factor AP1) [ 55 , 59 ]; telomerase reverse transcriptase (hTERT) [ 60 , 61 ]; eukaryotic translation initiation factors eIF4E and eIF4G, along with their binding partner 4E-BP1 (key components of the translational cap-binding complex) [ 62 , 63 ]; sodium/potassium adenosine triphosphatase (Na/K-ATPase) [ 64 , 65 ]; Notch (which plays a role in tumor cell invasion and metastasis) [ 66 ]; nuclear factor kappa B (NF-κB) [ 67 , 68 , 69 ]; mammalian target of rapamycin complex (mTORC) [ 61 , 70 ]; and transforming growth factor beta (TGFβ) [ 55 ]. Furthermore, POH was characterized as an effective trigger of endoplasmic reticulum (ER) stress, which was revealed through its ability to stimulate the expression of two ER stress markers, CCAAT/enhancer-binding protein homologous protein (CHOP, also known as GADD153) and glucose-regulated protein of molecular weight 78 kDa (GRP78, also known as BiP) [ 71 ]. CHOP represents the key pro-apoptotic effector of ER stress [ 72 ], and its prominently increased expression in response to the treatment of tumor cells with POH is consistent with resulting cell death. The tumor-selective impact of POH (and of other agents that are able to aggravate cellular stress levels) via the ER stress response was conjectured to be based on pre-existing, chronic stress levels in tumor cells, which are lacking in normal cells. In tumor cells, aggravated stress reaches the maximum tolerated threshold quicker, whereas normal cells have more leeway to accommodate and therefore tolerate these increased levels [ 73 , 74 ].

While a plethora of cellular POH targets was identified, the decisive contribution of each one has not yet been clearly established. It is likely that some targets are more critical than others, and cell-type-specific availability of some targets might factor in as well. Furthermore, in view of multiple alterations that are generally acquired during the carcinogenic process of tumor cell development, a pleiotropic impact on tumor cell functions might in fact be desirable and beneficial to achieve improved therapeutic outcomes.

3. Clinical Evaluation of Oral POH

Based on the well-documented, highly promising anticancer functions of POH that were characterized in a variety of preclinical in vitro and in vivo models, the agent was moved forward to clinical trials in humans. In the first of these trials [ 75 ], 18 patients with advanced malignancies received POH that was formulated in soft gelatin capsules containing 250 mg POH mixed with 250 mg soybean oil. Dosing was by mouth three times a day, every day, at escalating doses of up 2400 mg/m 2 /dose (approximately 4 g POH in 16 capsules per dose for a 60 kg patient; 12 g total per day). POH was generally tolerated, with gastrointestinal (GI) toxicities as the most frequent events, presenting as nausea, belching, vomiting, unpleasant taste, and early satiety, which were correlated with increasing dose levels and proved dose-limiting. Pharmacokinetic plasma measurements were able to quantify the major metabolites perillic acid and dihydro-perillic acid [ 75 ] but did not detect the parent compound POH, consistent with earlier studies in POH-fed rats that easily detected the terpene metabolites but not POH itself [ 43 ]. The metabolite half-lives were approximately 2 h and there was no evidence of drug or metabolite accumulation [ 75 ], which spawned the rationale to spread drug administration more evenly in the hopes of achieving greater exposure by increasing the dosing frequency. Therefore, in a subsequent Phase I trial, the dosing frequency was increased to four times a day at up to 1600 mg/m 2 /dose [ 76 ]. Similar GI toxicities as before were noted, and the maximum tolerated dose of POH was determined as 1200 mg/m 2 /dose (approximately 8 g total per patient per day from 32 capsules per day), which was recommended as the starting dose for Phase II studies.

Several Phase II trials with oral POH followed in cohorts of patients with advanced ovarian cancer [ 77 ], metastatic prostate cancer [ 78 ], metastatic breast cancer [ 79 ], metastatic androgen-independent pancreatic cancer [ 80 ], and metastatic colorectal cancer [ 81 ]. Dosing was four times each day for an initially planned 6-month period. As in the previous Phase I studies, the toxicity was mild to moderate and primarily limited to GI effects and fatigue, although there was significant variability in patient responses. Overall, however, the therapeutic activity of POH was unimpressive and mostly disappointing. Furthermore, while GI toxicity was not unacceptably severe based on common clinical criteria, the chronic and unrelenting nature of these effects caused problems with patient tolerance and compliance to the point where some patients discontinued their participation in these trials [ 77 , 78 , 81 ]. These results dampened the enthusiasm that was generated by the highly promising preclinical studies of POH and, so far, no Phase III clinical trials of orally administered POH have been initiated [ 82 ]. A newer route of administration, dosing POH intranasally rather than orally (so as to avoid the GI-related side effects), has revived some of the lost excitement and has sparked new hope that POH might still find its place among new and improved clinically used cancer therapeutics. The efforts to establish intranasal POH as a beneficial cancer treatment, in particular for cancer types in the brain that are protected by the BBB, are described below.

4. Intranasal Perillyl Alcohol

Intranasal drug delivery represents a non-invasive route of administration with several advantages over oral drug delivery. Although the extent of these advantages may differ significantly, based on the specifics of the delivery methods, drug formulation, and physicochemical properties of the active pharmacological ingredient (API), they usually include quicker biological availability, avoidance of hepatic first-pass metabolism, and potentially less systemic side effects. Moreover, the potential for direct nose-to-brain transport offers the prospect of increased central nervous system (CNS) drug availability by side-stepping the BBB [ 83 , 84 , 85 ].

As outlined in Figure 1 , after drugs have entered the nasal cavity, there are four main routes by which such drugs may reach the brain [ 83 , 86 , 87 , 88 ]: (#1) Direct nose-to-brain transport is offered through drug absorption by the olfactory bulb and through drug uptake by branches of the trigeminal nerve. This pathway is of particular interest for purposes of delivering drugs aimed at the brain, because it does not involve the drawbacks of having to overcome the BBB. (#2) Extensive vascularization of the nasal epithelium and a rich lymphatic network are conducive to effective drug uptake that will deliver the drug into the systemic circulation. However, subsequent brain uptake by this path will be subjected to the limitations of having to cross the BBB. (#3) Intranasally delivered drugs may also be inhaled or aspirated into the lungs, in particular when APIs are formulated as aerosols. From here, they effectively enter the bloodstream, only to again encounter the BBB as an obstacle on their way to the brain. (#4) Postnasal drip and mucociliary clearance result in drug transport to the GI tract. Depending on the lipophilicity of the drug and other properties, the API may continue through the portal vein and liver, or via intestinal lymphatic transport. The route via the portal vein poses the additional challenge of substantial drug metabolism, which may result in effective drug inactivation. In both these cases, the drug ends up in the systemic circulation and encounters the BBB.

Comparing the above four pathways illustrates the potential advantages of intranasal drug delivery. Only the first one, i.e., direct nose-to-brain transport, has the potential for direct delivery to the brain without encountering the obstacle placed by the BBB. While the efficiency of this route is very low in general and can be as low as 0.01–1% of the oral dosage [ 83 ] (depending in large part on biopharmaceutical formulation and physicochemical properties of the API [ 88 , 89 ]), this small amount can nevertheless prove advantageous over oral delivery due to avoidance of potentially inefficient absorption and elimination in the GI tract, hepatic first-pass metabolism, and dilution and protein binding in the bloodstream. Furthermore, several oral CNS drugs barely penetrate the BBB and, therefore, must be given at increased dosages that raise the risk for adverse effects in the periphery. This latter consideration applies to parenteral injections of drugs as well, further emphasizing the potential advantages of intranasal delivery. For further reading, see the following excellent reviews: [ 83 , 84 , 90 , 91 ].

4.1. Intranasal POH as Monotherapy

While several Phase I and II clinical trials of oral POH, as described above, yielded disappointing results and never moved into Phase III [ 92 ], a case report published in 2006 [ 93 ] stimulated renewed interest in POH by way of intranasal delivery. This report described a 62-year-old woman in Brazil with histologically confirmed anaplastic oligodendroglioma, a malignant grade III glioma. Despite standard combination therapy with surgery, radiotherapy, and chemotherapy, she presented with a second recurrency, at which time, intranasal POH (obtained from Sigma-Aldrich/MilliporeSigma, St. Louis, Missouri, USA) was initiated at 0.3% concentration and four times daily dosing. After 5 months of treatment, a follow-up MRI revealed regression of the tumor [ 93 ].

Based on this positive outcome, intranasal POH delivery was further investigated in additional relapsed glioma patients. A follow-up study reported on a small cohort of 37 patients with recurrent high-grade glioma, where the same four-times-daily POH regimen was administered intranasally (55 mg per dose for 220 mg total per day) [ 94 ]. Here as well, it was reported that this novel treatment strategy resulted in encouraging outcomes, with decreased tumor size ( Figure 2 ) and increased survival in several patients. Further expansion of these studies included several hundred recurrent patients with malignant glioma, including GBM, and dosing was further increased to 133 mg per dose (533 mg/day) [ 95 , 96 ]. Overall, these Phase I/II studies further indicated the encouraging therapeutic activity of intranasal POH, with numerous patients remaining under clinical remission even after several years of exclusive POH treatment. Of note, despite the four-times-daily dosing, this regimen was very well tolerated and adverse events were almost non-existent, contributing to very high patient compliance [ 96 ].

The above studies were performed in Brazil and are in part still ongoing. Despite the inclusion of hundreds of patients and numerous encouraging observations, limitations include the absence of an independent Contract Research Organization (CRO) for external clinical data management and trial monitoring. Inspired by the promising Brazilian experience, a Phase I/IIa study with recurrent GBM patients was initiated in the United States ( ClinicalTrials.gov identifier: NCT02704858 ) and the results from the Phase I part were published in early 2021 [ 97 ]. For this trial, POH had to be produced for pharmaceutical use under CGMP regulations, which yielded a highly pure (>99%) product that was labeled NEO100 (see Scheme 3 ). The dose finding in Phase I used four cohorts of three patients each and escalated the four-times-daily dose up to a maximum of 288 mg, for a total of 1152 mg/day, which represented roughly double the dosage used in the Brazilian trials.

This new study [ 97 ] found that intranasal NEO100 was very well tolerated, consistent with the earlier Brazilian trials’ findings. Among the 12 patients in Phase I, there were no grade 3 or 4 adverse events (based on NCI Common Terminology Criteria for Adverse Events [ 98 ]). Among the few lower-grade events defined as “definitely treatment-related” were rhinorrhea, skin irritation around the nose, nasal pruritus, and cough, which were observed in a minority of patients. Intriguingly, the frequency of these events did not correlate with increased dosages and, in fact, most of them were observed at the lowest dosage. It was concluded that intranasal delivery of NEO100 to recurrent GBM patients is safe [ 97 ] and free from the problematic side effects suffered from oral dosing.

Although Phase IIa of this trial is still ongoing, further analysis of Phase I data sought to provide preliminary insight into the activity of intranasal NEO100, which was determined based on radiographic responses, i.e., magnetic resonance imaging (MRI) performed every two months. Despite the small cohort of only 12 patients, there were intriguing signs of therapeutic benefit. Overall survival at 12 months (OS-12) was 55%, median OS was 15 months, and two-year survival was 37%. These results compared favorably with historical controls and other recent trials with cohorts of recurrent GBM patients ( Figure 3 ) [ 99 , 100 , 101 , 102 ]. For example, a 2018 retrospective [ 102 ] reviewed the clinical experience with bevacizumab, an anti-angiogenic monoclonal antibody that is approved for recurrent malignant glioma [ 103 ]. This analysis showed that therapy with bevacizumab yielded an OS-12 of 49%, median OS of 11 months, and two-year survival of 15%. A randomized Phase III trial with 65 recurrent GBM patients who received lomustine (also known as CCNU, a nitrosourea-based DNA alkylating agent commonly used in the recurrent GBM setting [ 104 ]), yielded an OS-12 of 30% and 2-year survival of below 4% [ 100 ]. Among such comparisons, it remains noteworthy to emphasize the lack of serious adverse events with the use of intranasal POH/NEO100, which is not the case for the majority of other commonly used therapies applied to recurrent GBM. Thus, even if there are only relatively small increments in survival in comparison to other regimens, quality of life (QoL) issues need to be factored into treatment decisions as well. Furthermore, maintenance of QoL for longer periods may increase the chances that further salvage therapies could be considered subsequent to a later recurrence (given enhanced patient strength and robustness for additional therapies compared with the outcomes after more debilitating conventional cytotoxic treatments).

As with most cancer therapies, efforts are underway to establish predictors of response to intranasal therapy with POH. One such study indicated that patients with recurrent GBM and treated with intranasal POH survived significantly longer when tumors were located deep in the basal ganglia as compared to lobar localization [ 105 ]. Another study provided preliminary evidence that those recurrent GBM patients harboring a hypermethylated tumor phenotype and preferential concurrent polymorphism for the thymidine-thymidine (TT) variant of rs1801133 of the methylene-tetrahydrofolate reductase (MTHFR) gene appeared to respond more favorably to intranasal POH, as indicated by prolonged survival [ 106 ]. Furthermore, isocitrate dehydrogenase 1 (IDH1) and IDH2 are emerging as potentially useful markers [ 107 ]. Specific mutations in either of these genes result in a neomorphic phenotype of the encoded protein, where enzymatic activity switches from the production of alpha-ketoglutarate to the synthesis of D-2-hydroxyglutarate [ 108 ]. In the case of newly diagnosed malignant glioma, such mutations in either IDH1 or IDH2 result in a better prognosis irrespective of the selected treatment approach [ 109 ], although this has not yet been firmly established for recurrent GBM [ 110 ]. Data from the above-described Phase I trial of NEO100 were separated into IDH-wild type and IDH-mutant cases, which revealed pronounced survival advantage for those intranasal NEO100-treated patients that harbored IDH-mutant tumors [ 97 ]. Due to the small cohort in this study, it remains to be established whether this survival advantage is primarily based on IDH status (and possibly enhanced by NEO100) or whether intranasal NEO100 contributes the decisive benefit. The currently ongoing Phase IIa part of this study is expected to provide clarification.

In the meantime, other ongoing studies are building on the highly promising results obtained with intranasal POH by exploring respective combination approaches. For instance, a case study [ 111 ] reported a 51-year-old woman with inoperable GBM who had recurred after standard treatment with TMZ-based chemoradiotherapy and subsequently was enrolled in a clinical trial of intranasal POH concomitant with oral TMZ. After initiation of POH + TMZ, MRI scans revealed a marked reduction of the initially enhanced lesion, and no recurrences were noted over the following two years. This provided an encouraging example where the combination approach appeared to demonstrate benefit in this case of non-resected recurrent GBM. Other efforts sought to explore the combination of intranasal POH with dietary interventions. In one such study [ 112 ], 32 recurrent GBM patients were enrolled and divided into two groups, one where intranasal POH was combined with a ketogenic diet (KD) and one where intranasal POH was given without any specific dietary intervention. After 90 days of treatment, the average tumor area in the combination group showed greater reduction as compared to baseline at time 0, suggesting more effective therapeutic activity. A similar approach, this time with 29 recurrent GBM patients and combined with a low carbohydrate diet (LCD) also showed a trend for the greater activity of intranasal POH when combined with an LCD [ 113 ].

Collectively, the above studies established POH as the best-studied intranasally delivered anticancer agent. As of 2021, there are patients who have been using this regimen uninterrupted for many years, indicating the prospect that this form of circumventing the BBB might be able to convert a deadly disease to a chronic one, at least in some of the patients.

Among the challenges of studying brain-targeted delivery of POH has been the difficulty of performing neuro-pharmacokinetic measurements of this compound. As mentioned above in the context of clinical trials with oral POH, PK measurements of blood levels relied on the quantification of the stable metabolite perillic acid because POH was not detectable with the analytical methods used. However, more sensitive and optimized approaches have become available. For instance, Zhang et al. reported on their detection of intact POH and perillic acid in plasma from a patient after oral delivery of POH using gas chromatographic–mass spectrometry (GC-MS) [ 114 ]. In studies with mice or rats, other groups applied ultra-performance liquid chromatography/tandem mass spectrometry (UPLC-MS/MS) [ 115 ] or high-performance liquid chromatography (HPLC)–ultraviolet (UV)-based approaches [ 116 ] to quantitate POH (and perillic acid) in the plasma and lungs of animals after intranasal delivery of POH. In a very recent study that investigated the impact of intranasal POH in a mouse model of cerebral malaria, the authors succeeded in quantifying POH in brain tissue using GC-MS [ 117 ]. Using a rat model, Nehra et al. quantitated POH (and perillic acid) levels in plasma and cerebrospinal fluid (CSF) after intranasal and intravascular POH delivery [ 118 ]. Very interestingly, this group was able to demonstrate that intranasal administration of POH resulted in tenfold higher CSF-to-plasma ratios for POH and perillic acid as compared to what was achieved after an equal dose of POH was administered intravascularly. While neuro-PK data are not yet available from patients, the results from these preclinical studies further indicate that intranasal administration of POH results in direct nose-to-brain delivery, further underscoring the potential value of this mode of drug delivery for brain cancer therapy.

4.2. Intranasal POH as a Co-Delivery System

Co-delivery systems for drug delivery come in many designs. They may comprise carriers, where one or more drugs are packaged into liposomes, nanoparticles, hydrogels, dendrimers, or other vehicles [ 119 , 120 ], and some of these are being developed specifically for the purpose of intranasal delivery to reach the brain via the nose-to-brain route [ 121 , 122 ]. Studies with POH have also revealed characteristics that make this monoterpenoid suitable for the purpose of transporting other drugs directly to the brain via the nose-to-brain route.

For instance, the intranasal delivery of NEO100, in combination with bortezomib, was investigated in rodent models of GBM [ 123 ]. Bortezomib (Velcade ® ) is a proteasome inhibitor that was approved to treat multiple myeloma and mantle cell lymphoma [ 124 ]. Its penetration of the BBB is extremely poor [ 125 ], which is consistent with its demonstrated lack of therapeutic effect in mouse GBM models [ 126 , 127 ] or when tested in the clinic with recurrent glioma patients [ 128 , 129 , 130 ] after intravenous delivery. In stark contrast, bortezomib showed high activity in mouse models of orthotopic GBM when it was delivered directly into the tumor using an Alzet pump [ 127 ], and at low nanomolar concentrations against glioma cells in vitro [ 131 , 132 , 133 ]. Collectively, these observations indicate that, in principle, bortezomib can be highly effective against GBM, but in reality, this benefit cannot be realized due to the agent’s inability to penetrate the BBB. In an attempt to circumvent this obstacle, bortezomib was mixed with NEO100 and delivered intranasally to mice harboring xenografted human GBM cells in their brains. Results from this study [ 123 ] demonstrated that the co-delivery of bortezomib with NEO100 significantly prolonged the survival of tumor-bearing animals as compared to untreated mice, mice receiving intranasal bortezomib in the absence of NEO100, or mice receiving bortezomib via intravenous infusion. Furthermore, the authors were able to demonstrate substantially greater amounts of bortezomib in the cerebrospinal fluid (CSF) of rats after treatment with the bortezomib/NEO100 combination than after treatment with bortezomib alone. Together, these studies provided proof of principle that a pharmacologic agent with very poor BBB penetration can effectively be delivered to the brain by using a NEO100-based formulation and intranasal delivery, where the amphiphilic physicochemical properties of NEO100 serve to increase permeation of both components through the BBB and cell membranes.

5. Intra-Arterial Perillyl Alcohol

While intranasal applications of POH and NEO100 exploit direct nose-to-brain access routes and thereby circumvent the obstacle placed by the BBB, an intra-arterial path of administering NEO100 has provided evidence that it also can directly confront the BBB and “open” it, i.e., diminish its barrier function to enable mostly unrestricted permeation of otherwise BBB-impermeable compounds. This procedure is being explored and characterized in preclinical models and might have certain advantages over the currently established clinical method of opening the BBB with mannitol.

Intracarotid injection of mannitol has been used for the past three decades as a means to reversibly open the BBB. Its disruptive mechanism is based on the contraction of endothelial cells and the resulting widening of tight junctions as a result of the hyperosmotic impact of high concentrations of this sugar alcohol. However, this procedure has led to variable responses in BBB breakdown, seizures, risk of brain embolism, and catastrophic bleeds [ 134 , 135 ]. As a result, the use of this procedure is restricted to specialized centers, has not found widespread acceptance, and does not lend itself to use in general clinical practice. Similarly, the effects of radiation on BBB permeability have long been recognized [ 136 ] and are thought to impact BBB integrity through the killing of endothelial cells and resulting neuro-inflammatory reactions [ 137 ]. However, many details, including the time course and magnitude of increased opening, remain to be established [ 138 ]. A more recently introduced BBB disruption technique is transcranial-focused ultrasound coupled with intravenously delivered microbubbles [ 139 ], which has advanced to clinical trials [ 140 , 141 ]. This procedure disrupts the BBB through cavitation and acoustic forces, leading to reduced expression of tight junction proteins, along with an inflammatory response. However, it represents a rather invasive procedure because the skull needs to be opened in order to introduce the ultrasound probe that triggers BBB permeation. Overall, despite progress in the development of new procedures, the need for safer, more efficient, and reversible BBB-opening methods persists [ 142 ].

Based on the use of preclinical models, intra-arterial injection of NEO100 was very recently presented as a novel BBB-disruptive method [ 143 , 144 ]. In these studies, intra-arterial injections of NEO100 were accomplished via ultrasound-guided intracardiac injections in mouse models, which resulted in rapid BBB opening that lasted up to four hours. During this window of opportunity, intravenously delivered agents were able to effectively enter the brain. For instance, Evans blue present in the systemic circulation was shown to prominently stain mouse brains blue after NEO100-induced BBB opening. This effect was not achieved via intra-arterial injection of a vehicle without NEO100, nor in cases where NEO100 was injected intravenously instead of intra-arterially (possibly due to dilution by the circulatory system and surrounding tissue). The mechanism of action of NEO100-induced BBB opening was demonstrated to be secondary to transient downregulation of specific gap junction proteins, resulting in short-term, fully reversible breakdown of barrier function [ 143 , 144 ]. Similar outcomes were seen with the non-BBB-permeable anticancer drug methotrexate, which accumulated to high levels in brain tissue and CSF after NEO100-induced BBB opening. Intriguingly, increased brain entry was not limited to small therapeutic molecules, such as methotrexate, but could also be documented for therapeutic antibodies, e.g., a checkpoint-inhibitory anti-PD1 antibody and the anti-HER2 antibody trastuzumab, and even for whole cells, using chimeric antigen receptor (CAR) T cells as a model [ 144 ]. Furthermore, these authors provided proof of principle that NEO100-based BBB opening is able to achieve therapeutic benefit in mouse models of intracranially implanted HER2+ breast cancer cells [ 143 ]. Mice harboring such tumors were subjected to a single round of intra-arterial injection of NEO100, along with intravenous delivery of trastuzumab or the trastuzumab-drug conjugate ado-trastuzumab emtansine (T-DM1; Kadcyla ® ). There was a tumor-selective accumulation of these therapeutic antibodies in the brain and significantly prolonged survival of mice receiving this treatment.

With regard to translating the above preclinical results to patient applications, it was proposed [ 143 ] that patients with intracranial malignancies would be subjected to standard interventional neuroradiology that would allow for selective delivery of NEO100 to tumor-feeding intracranial arteries. Intra-arterial injections would be performed via cannulation of the femoral artery with selective threading toward one of the cerebral arteries. This transfemoral approach [ 145 , 146 , 147 ] represents a common, straightforward procedure in a variety of clinical settings and is generally considered a safe procedure [ 148 , 149 , 150 ]. It is routinely performed by endovascular neurosurgeons in the context of cerebral angiograms, aneurysm coiling, tumor embolization, and thrombectomies [ 151 ]. Combining this transfemoral approach with NEO100 as the injectate has not yet been tested in the clinic. However, if the safety of transient BBB opening with this approach could be confirmed, it would have far-reaching implications. It would provide a significantly safer alternative to intracarotid mannitol, its use would not be restricted to specialized medical centers, and its application would expand to include the treatment of many neurological diseases beyond intracranial malignancies.

6. Perillyl Alcohol Derivatives, Analogs, and Conjugates

Based on the recognition of POH’s suitable physicochemical properties in combination with its anticancer activity, numerous studies have explored whether alterations and modifications of this molecule might result in enhanced therapeutic activity. For instance, the glycosylation of drugs can often significantly alter their pharmacological properties and ADMET (absorption, distribution, metabolism, excretion, and toxicity) [ 152 ]. Glycosides of POH exist in nature and some of them were initially characterized as aldose reductase inhibitors [ 153 ]. Additional unnatural POH derivatives were synthesized and tested for their potential anticancer activity [ 154 , 155 , 156 ]. For instance, Nandurkar et al. [ 155 ] generated a group of 34 POH glycosides that were tested for their antiproliferative activity against two established cancer cell lines in vitro. This group identified several new compounds that exerted greater in vitro cytotoxicity than POH, with POH 4′-azido-D-glucoside as the most potent POH adduct. Similarly, a series of cyclodiprenyl phenols were synthesized from perillyl alcohol and synthetic phenols, and some of these meroterpenes showed strong antiproliferative and apoptosis-inducing activity against three different cancer cell lines in vitro [ 157 ]. POH was also complexed with β-cyclodextrin, which resulted in improved anticancer potency in vitro and in a sarcoma S180-induced mouse model in vivo [ 158 ]. Beyond these selected examples, several more reports on modified POH (or perillic acid) molecules exist, and the interested reader is referred to excellent recent reviews [ 159 , 160 ] for additional information and detailed references.

Some hybrid drugs are generated as multifunctional compounds, where two or more molecules with already well-characterized pharmacologic activity are conjugated through a stable or metabolizable linker. The central rationale of associating these pharmacophores is to increase their potency, to possibly enable overall dosing at lower levels to minimize toxic side effects, and to reduce the likelihood of emerging drug resistance [ 161 , 162 ]. For example, it was investigated [ 163 ] whether linking POH to dihydropyrimidinones would generate increased anticancer impact. Dihydropyrimidinones are important heterocyclic compounds and, like POH, have revealed a large scope of pharmacological activities, including anticancer properties [ 164 ]. Fifteen novel perillyl–dihydropyrimidinone compounds were generated and some of them were found to effectively kill established ovarian cancer, melanoma, and glioblastoma cell lines, but spared a normal keratinocyte cell line [ 163 ]. The cytotoxic IC 50 ratio between the keratinocyte cell line and the glioblastoma cell line was about 50, meaning that 50-fold higher drug concentrations were required to kill the normal cells as compared to the tumor cells, indicating promising cancer cell-selectivity of some of these novel compounds.

6.1. Conjugation with POH to Enhance Permeability

In a different approach toward generating POH-based multifunctional compounds, the group of Thomas Chen at the University of Southern California sought to exploit the amphipathic nature of POH to modify existing drugs toward increased penetration of biological barriers, in particular the BBB. Using software from Advanced Chemistry Development, Inc. (ACD Labs, Toronto, ON, Canada), to predict BBB penetration and brain entry of a given molecule, they performed in silico characterization of novel molecules, where POH was conjugated to pharmacologic agents of interest with the objective to identify therapeutics with superior ability to enter the brain.

6.1.1. POH Conjugated to Temozolomide (NEO212)

The so-far best-characterized hybrid molecule emerging from in silico studies of BBB penetration is NEO212 ( Figure 4 ), consisting of POH covalently conjugated via a carbamate bond to TMZ, the alkylating agent in clinical use for GBM. NEO212 has been investigated in over a dozen studies that used a variety of preclinical in vitro and in vivo tumor models and consistently established the robust anticancer activity of this novel molecule, along with low toxicity [ 165 , 166 , 167 , 168 ] and superior ability to penetrate the BBB [ 169 ].

Among the remarkable results was the finding that the NEO212 hybrid molecule exerted greater anticancer activity than an equimolar mix of its individual constituents, i.e., combining POH with TMZ—akin to the conventional combination therapy mode—was unable to achieve the same tumoricidal potency in vitro or in vivo as the conjugated molecule, indicating that the activity of the conjugated compound was greater than the sum of its parts [ 165 , 166 , 167 , 168 , 170 ]. For example, the effects of NEO212 were investigated in mouse brain tumor models of GBM [ 170 , 171 ] or intracranial breast cancer (to mimic brain-metastatic conditions) [ 165 ]. It was demonstrated that oral treatment with NEO212 exerted greater therapeutic activity than equivalent doses of TMZ or POH, either individually or when combined. When compared side by side and given at equal doses, the amount of NEO212 measured in brain tissue was threefold higher than the amount of TMZ [ 169 ], confirming the in silico results, where NEO212 was predicted to cross the BBB more efficiently than TMZ.

NEO212’s superior penetration ability was not restricted to having the BBB as the target. Cellular membranes present important biological barriers too, and here, NEO212 revealed beneficial characteristics as well. In a key in vitro experiment, it was measured how much TMZ was present inside cells after treatment of cells with equal concentrations of either NEO212 or TMZ [ 169 ]. The results showed >10-fold higher intracellular TMZ levels when cells were treated with NEO212 as compared to treatment of cells with TMZ [ 169 ]. Similarly, the expected metabolite of TMZ breakdown, the relatively stable 5-aminoimidazole-4-carboxamide (AIC), was correspondingly elevated as well, indicating that NEO212-treated cells generated substantially more of the active, DNA-alkylating species than TMZ-treated cells. Overall, these observations are consistent with a model where the conjugation of POH to TMZ enables superior barrier penetration and consequential enhancement of the anticancer impact of the TMZ partner molecule, qualifying POH as a potent permeation enhancer.

Based on the highly efficient cellular uptake of NEO212, it was hypothesized [ 167 ] that NEO212 might also exert a beneficial impact on leukemic cancer types, where the encounter between drug and tumor cells might be more immediate and most conducive to optimal drug uptake. The veracity of this conjecture was tested in acute myeloid leukemia (AML) cells in vitro and in vivo, which included AML cell lines that were strongly resistant to cytosine arabinoside (AraC), the most commonly used chemotherapeutic agent for this disease [ 172 ]. The in vitro experiments showed potent cytotoxic activity of NEO212 at low micromolar concentrations, along with confirmation that TMZ and its breakdown product AIC were present at high levels inside NEO212-treated AML cells. The most striking results were generated when AML cells were implanted into immunocompromised mice, followed by short cycles of NEO212 treatment. In these in vivo experiments, the majority of NEO212-treated animals survived until the end of the observation period (300 days), while all vehicle-treated control animals succumbed to disease within a few weeks [ 167 ]. The same outcome was achieved with AraC-resistant AML cell lines. Although the authors did not verify whether the NEO212 treatment was eradicative, i.e., whether residual, potentially dormant tumor cells were still present after 300 days, they concluded that treatment was curative, because the long-term survivors continued to thrive in the absence of any signs of disease.

The strikingly impressive therapeutic activity of NEO212 in this preclinical leukemia model is consistent with the above-stated assessment of POH as a permeation enhancer, in this case, for conjugated TMZ as the partner. However, it raises the question of tumor specificity and toxic side effects because normal cells—bone marrow cells and white blood cells (WBC) in particular—might be as susceptible as tumor cells. In the case of TMZ, for example, myelosuppression is a well-recognized, dose-limiting side effect of treatment [ 173 ]. Surprisingly, however, detailed analysis of complete blood counts (CBC) from NEO212-treated mice, together with histopathology of bone marrow and several other organs, failed to reveal signs of toxicity in these compartments [ 165 , 166 , 167 , 168 ]. Instead, NEO212 appeared to be very well tolerated, even during extended treatment periods and escalated dosages [ 167 ]. While this wide therapeutic window observed in these preclinical studies bodes well for future clinical applications, the underlying determinants of tumor selectivity of NEO212 remain to be established.

6.1.2. POH Conjugated to Rolipram or 3-Bromopyruvate or Valproic Acid

Beyond NEO212, other POH-based conjugates emerged from in silico analysis using ACD Lab’s software that predicted greater BBB penetration and possibly increased membrane permeation. NEO214 is a conjugate of POH and rolipram, a selective phosphodiesterase 4 (PDE4) inhibitor that was in clinical development as an anti-depressant in the 1990s. Although rolipram was never approved for marketing [ 174 ], it was considered for repurposing as an anticancer agent based on its recognized beneficial activity in preclinical cancer models [ 175 , 176 ]. In mouse models of intracranial glioblastoma, NEO214 revealed significant therapeutic activity [ 177 ], indicating that it was indeed able to effectively cross the BBB, as was predicted from the in silico analysis. Intriguingly, as was observed with NEO212, combination therapy with the individual components, i.e., POH mixed with rolipram, was unable to mimic the much stronger anticancer effects of the conjugated NEO214 molecule [ 177 , 178 ].

Another interesting observation was made with NEO218, a conjugate of POH and 3-bromopyruvate (3BP), a synthetic halogenated derivative of pyruvate that was also investigated as an anticancer agent [ 179 ]. Cellular uptake of 3BP is strictly dependent on the presence of a transmembrane transport protein mono-carboxylate transporter 1 (MCT-1), where cells lacking MCT-1 are resistant to the toxic impact of 3BP [ 180 ]. It was demonstrated that applying selective pressure to MCT-1-positive HCT116 colon carcinoma cells by exposing them to 3BP in vitro resulted in the elimination of transporter-positive cells, with the simultaneous emergence of an MCT-1-negative sub-population that displayed resistance to 3BP [ 181 ]. In comparison, NEO218 exerts its cytotoxic impact in the absence of MCT-1, i.e., the conjugation of POH to 3BP enabled cellular 3BP import across the cytoplasmic membrane without the need for an active transport mechanism. Consequently, treatment of HCT116 cells with NEO218 did not result in emergent resistant clones, because the loss of MCT-1 expression could not provide a survival advantage [ 181 ], providing an example of POH’s applicability to minimize the emergence of cancer cell drug resistance during therapy.

Yet another conjugate, NEO216, which is POH covalently linked to valproic acid (VPA), was preliminarily characterized. Compared to VPA, a well-known inhibitor of histone deacetylase (HDAC) activity [ 182 ], NEO216 showed reduced HDAC inhibition properties but revealed an ability to inhibit 4-aminobutyrate aminotransferase (ABAT), a key enzyme responsible for the catabolism of the neurotransmitter gamma-aminobutyric acid (GABA) [ 183 ]. This novel function has made NEO216 useful for a recent study that established the role of GABA metabolism in leptomeningeal dissemination of medulloblastoma [ 183 ] and more applications of this novel conjugate are anticipated.

6.2. POH and Penetration of the Skin

Similar to intranasal delivery, transdermal drug delivery (TDD) is being explored as an alternative route to other modes of drug administration, as it too has certain advantages that include the avoidance of hepatic first-pass drug metabolism, reduced GI side effects, and good patient compliance. The key barrier to efficient TDD is presented by the stratum corneum, the outermost layer of the epidermis that can severely limit percutaneous drug absorption [ 184 , 185 ]. To overcome this barrier, a great variety of chemical compounds have been investigated for their use as potential skin penetration enhancers, i.e., as promoters or accelerants to enable and increase the transdermal flux of topically applied pharmacologic agents (see details and further references in excellent reviews [ 186 , 187 ]). While many terpenes were identified as potential skin penetration enhancers [ 188 , 189 ], POH stands out among them because it also appears to exert beneficial transdermal activity on its own, i.e., without the need for other co-transported therapeutic agents.

For instance, when applied topically to the skin, POH was able to inhibit tumor development in the skin of mice exposed to the carcinogen DMBA [ 190 , 191 ] or to ultraviolet B radiation [ 192 ]. These preclinical observations prompted clinical studies to investigate whether topical application of POH might prove effective as a skin cancer chemoprevention strategy. A Phase I study enrolled participants with normal, healthy skin who applied POH, formulated as a cream [ 193 ], to their forearms twice daily for 30 days. The results showed that the POH cream was well tolerated and no cutaneous or systemic toxicities were observed [ 194 ]. In a subsequent Phase IIa study with POH cream and twice-daily applications to the forearms of participants over three months, it was investigated whether this treatment could reverse actinic (sun) damage. Modest effects of POH in sun-damaged skin could be documented, but the overall outcome was unimpressive [ 195 ], and no follow-up studies have been reported since. In other investigations, the authors used two murine models of dermatitis (induced by 12-O-tetradecanoylphorbol-13-acetate (TPA)) and of mechanical skin lesions (induced by epidermal incisions) that received daily treatments with topical POH prepared in sunflower oil. These studies showed that POH exerted significant anti-inflammatory effects along with improved tissue repair and wound healing [ 196 ]. Related observations were made with a mouse model of neuronal injury (although, in these cases, POH was given orally), where POH reduced gliosis and improved sensory and motor function recovery [ 197 ].

Among the above-introduced POH hybrid molecules, NEO412 was designed as a topical treatment for melanoma in situ (MIS). Although MIS has a better prognosis than metastatic melanoma, its effective treatment is complicated by ill-defined margins during surgical removal of the lesions, potentially leading to invasive melanoma [ 198 ]. Therefore, a topical treatment that would target unrecognized malignant components that might remain after surgery could be of great benefit to minimize the risk of recurrence. NEO412 is a tripartite agent consisting of three bioactive agents: POH, TMZ, and linoleic acid, with the latter representing a well-established transdermal penetration enhancer [ 199 , 200 ]. In vitro studies confirmed that NEO412 was able to effectively kill melanoma cells through the alkylation effect of TMZ [ 201 ]. In a mouse model of subcutaneous melanoma, topical application of NEO412 increased tumor cell death, along with decreased neo-angiogenesis in tumor tissue. Intriguingly, these effects could also be observed in tumors that were located distant from the skin treatment site, indicating that topical NEO412 was able to enter the circulation and reach tumor cells that might have metastasized already [ 201 ]. Although it remains to be established how much each penetration enhancer, i.e., POH vs. linoleic acid, contributed to transdermal migration of the tripartite molecule, the significant anti-melanoma effect that was achieved clearly indicates the benefit of this combination.

7. Conclusions and Outlook

POH is a monoterpenoid with an amphipathic character that appears to provide the physicochemical basis for its multifaceted applicability to overcome biological barriers. By means of further purification and CGMP manufacture, an effective pharmaceutical agent, namely, NEO100, was realized from POH that demonstrates good therapeutic prospects from in vitro, in vivo, and clinical testing. It can circumvent the BBB when administered via the intranasal route or physically open the BBB when given intra-arterially. It easily penetrates the cytoplasmic membrane without the need for cell surface transport proteins to facilitate its cell entry. In addition, it appears to harbor skin-penetrating potency. While much research has focused on characterizing the anticancer activity of the POH molecule, other avenues of investigation have further established its ability to enhance the therapeutic impact of different pharmacologic agents, either through enabling the transport of BBB-impermeable drugs via the intranasal route directly into the brain or through its covalent conjugation to specific drugs that results in overall increased penetration of the above-described biological barriers by the conjugated molecule.

The general principles attributed to the use of POH for increasing permeability across various biological barriers represent platform technologies that could be applicable to multiple clinical needs and situations. Although the bulk of applications is currently outlined for the treatment of primary and metastatic brain tumors, these POH-based concepts are adaptable for use in therapies aimed at neurodegenerative and infectious conditions of the brain. Moreover, the variety of molecules that could be delivered to the brain with the use of these platforms is not restricted to established drugs, but may include nucleic acids, i.e., siRNA, miRNA, and mRNA, as well as therapeutic proteins and antibodies, and possibly even intact cells and stem cells.

Acknowledgments

We thank all current and previous members of our laboratories for their valuable contributions.

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author Contributions

A.H.S. assembled an outline of this review. T.C.C., C.O.d.F. and D.L. contributed to the writing and revising of the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

Studies in the authors’ labs were supported in part through generous funding provided by the Hale Family Research Fund, Garza Foundation, and Sounder Foundation (to T.C.C.), and by the California Breast Cancer Research Program and METAvivor (to A.H.S.). The funding sources had no role in the design of the studies and collection, analysis, or interpretation of the data.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

T.C.C. and C.O.d.F. are founders and stakeholders of NeOnc Technologies, Inc., Los Angeles, California, USA. D.L. is a shareholder and member of the science advisory board of NeOnc. A.H.S. declares no potential conflict of interest.

Abbreviations

References

1. Smith Q.R. A Review of Blood–Brain Barrier Transport Techniques Methods Mol. Med. 2003 89 193 208 10.1385/1-59259-419-0:193 12958421

2. Obermeier B. Daneman R. Ransohoff R.M. Development, maintenance and disruption of the blood-brain barrier Nat. Med. 2013 19 1584 1596 10.1038/nm.3407 24309662 PMC4080800

3. Langen U.H. Ayloo S. Gu C. Development and Cell Biology of the Blood-Brain Barrier Annu. Rev. Cell Dev. Biol. 2019 35 591 613 10.1146/annurev-cellbio-100617-062608 31299172 PMC8934576

4. Sharif Y. Jumah F. Coplan L. Krosser A. Sharif K. Tubbs R.S. Blood brain barrier: A review of its anatomy and physiology in health and disease Clin. Anat. 2018 31 812 823 10.1002/ca.23083 29637627

5. Frisk G. Svensson T. Bäcklund L.M. Lidbrink E. Blomqvist P. E Smedby K. Incidence and time trends of brain metastases admissions among breast cancer patients in Sweden Br. J. Cancer 2012 106 1850 1853 10.1038/bjc.2012.163 22531629 PMC3364124

6. Kim Y.-J. Kim J.-S. Kim I.A. Molecular subtype predicts incidence and prognosis of brain metastasis from breast cancer in SEER database J. Cancer Res. Clin. Oncol. 2018 144 1803 1816 10.1007/s00432-018-2697-2 29971531 PMC11813522

7. Krishnan M. Krishnamurthy J. Shonka N. Targeting the Sanctuary Site: Options when Breast Cancer Metastasizes to the Brain Oncology 2019 33 683730 31469897

8. Garcia-Alvarez A. Papakonstantinou A. Oliveira M. Brain Metastases in HER2-Positive Breast Cancer: Current and Novel Treatment Strategies Cancers 2021 13 2927 10.3390/cancers13122927 34208287 PMC8230933

9. Aulakh S. DeDeo M.R. Free J. Rosenfeld S.S. Quinones-Hinojosa A. Paulus A. Manna A. Manochakian R. Chanan-Khan A.A. Ailawadhi S. Survival trends in glioblastoma and association with treating facility volume J. Clin. Neurosci. 2019 68 271 274 10.1016/j.jocn.2019.04.028 31133366 PMC8006067

10. Efremov L. Abera S.F. Bedir A. Vordermark D. Medenwald D. Patterns of glioblastoma treatment and survival over a 16-years period: Pooled data from the german cancer registries J. Cancer Res. Clin. Oncol. 2021 147 3381 3390 33743072 10.1007/s00432-021-03596-5 PMC8484256

11. Louis D.N. Perry A. Wesseling P. Brat D.J. A Cree I. Figarella-Branger D. Hawkins C. Ng H.K. Pfister S.M. Reifenberger G. The 2021 WHO Classification of Tumors of the Central Nervous System: A summary Neuro-Oncology 2021 23 1231 1251 10.1093/neuonc/noab106 34185076 PMC8328013

12. Frappaz D. Bonneville-Levard A. Ricard D. Carrie S. Schiffler C. Xuan K.H. Weller M. Assessment of Karnofsky (KPS) and WHO (WHO-PS) performance scores in brain tumour patients: The role of clinician bias Support. Care Cancer 2021 29 1883 1891 10.1007/s00520-020-05663-y 32789684

13. Stupp R. Mason W.P. van den Bent M.J. Weller M. Fisher B. Taphoorn M.J. Belanger K. Brandes A.A. Marosi C. Bogdahn U. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma N. Engl. J. Med. 2005 352 987 996 10.1056/NEJMoa043330 15758009

14. Stupp R. Hegi M.E. Mason W.P. van den Bent M.J. Taphoorn M.J.B. Janzer R.C. Ludwin S.K. Allgeier A. Fisher B. Belanger K. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol. 2009 10 459 466 10.1016/S1470-2045(09)70025-7 19269895

15. Kazda T. Dziacky A. Burkon P. Pospisil P. Slavik M. Řehák Z. Jancalek R. Slampa P. Slaby O. Lakomy R. Radiotherapy of glioblastoma 15 years after the landmark Stupp’s trial: More controversies than standards? Radiol. Oncol. 2018 52 121 128 10.2478/raon-2018-0023 30018514 PMC6043880

16. Ostermann S. Csajka C. Buclin T. Leyvraz S. Lejeune F. Decosterd L. Stupp R. Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Temozolomide in Malignant Glioma Patients Clin. Cancer Res. 2004 10 3728 3736 10.1158/1078-0432.CCR-03-0807 15173079

17. Portnow J. Badie B. Chen M. Liu A. Blanchard S. Synold T. The Neuropharmacokinetics of Temozolomide in Patients with Resectable Brain Tumors: Potential Implications for the Current Approach to Chemoradiation Clin. Cancer Res. 2009 15 7092 7098 10.1158/1078-0432.CCR-09-1349 19861433 PMC2908372

18. Guyon J. Chapouly C. Andrique L. Bikfalvi A. Daubon T. The Normal and Brain Tumor Vasculature: Morphological and Functional Characteristics and Therapeutic Targeting Front. Physiol. 2021 12 622615 10.3389/fphys.2021.622615 33746770 PMC7973205

19. Wang D. Wang C. Wang L. Chen Y. A comprehensive review in improving delivery of small-molecule chemotherapeutic agents overcoming the blood-brain/brain tumor barriers for glioblastoma treatment Drug Deliv. 2019 26 551 565 10.1080/10717544.2019.1616235 31928355 PMC6534214

20. Boogerd W. Groenveld F. Linn S. Baars J.W. Brandsma D. Van Tinteren H. Chemotherapy as primary treatment for brain metastases from breast cancer: Analysis of 115 one-year survivors J. Cancer Res. Clin. Oncol. 2012 138 1395 1403 10.1007/s00432-012-1218-y 22526158 PMC11824332

21. Franciosi V. Cocconi G. Michiara M. Di Costanzo F. Fosser V. Tonato M. Carlini P. Boni C. Di Sarra S. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: A prospective study Cancer 1999 85 1599 1605 10.1002/(SICI)1097-0142(19990401)85:7<1599::AID-CNCR23>3.0.CO;2-# 10193952

22. Lockman P. Mittapalli R.K. Taskar K.S. Rudraraju V. Gril B. Bohn K.A. Adkins C.E. Roberts A. Thorsheim H.R. Gaasch J.A. Heterogeneous Blood–Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer Clin. Cancer Res. 2010 16 5664 5678 10.1158/1078-0432.CCR-10-1564 20829328 PMC2999649

23. Sarkaria J.N. Hu L.S. Parney I.F. Pafundi D.H. Brinkmann D.H. Laack N.N. Giannini C. Burns T.C. Kizilbash S. Laramy J.K. Is the blood–brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data Neuro-Oncology 2018 20 184 191 10.1093/neuonc/nox175 29016900 PMC5777482

24. Pitz M.W. Desai A. Grossman S.A. Blakeley J.O. Tissue concentration of systemically administered antineoplastic agents in human brain tumors J. Neuro-Oncol. 2011 104 629 638 10.1007/s11060-011-0564-y 21400119 PMC4020433

25. Arvanitis C.D. Ferraro G.B. Jain R.K. The blood–brain barrier and blood–tumour barrier in brain tumours and metastases Nat. Rev. Cancer 2020 20 26 41 10.1038/s41568-019-0205-x 31601988 PMC8246629

26. Marcucci F. Corti A. Ferreri A. Breaching the Blood–Brain Tumor Barrier for Tumor Therapy Cancers 2021 13 2391 10.3390/cancers13102391 34063335 PMC8156088

27. Crowell P.L. Elson C.E. Isoprenoids, health and disease Neutraceuticals and Functional Foods Wildman R.E.C. CRC Press Boca Raton, FL, USA 2001

28. Pan J. Xu Z. Ji L. Zhao Z. Tang X. Constituents of Essential Oils from Leaves, Stems, and Fruits of Perilla frutescens (L.) britt Zhongguo Zhong Yao Za Zhi 1992 17 164 192 164–165, 192 1418538

29. Shojaei S. Kiumarsi A. Moghadam A.R. Alizadeh J. Marzban H. Ghavami S. Perillyl Alcohol (Monoterpene Alcohol), Limonene Struct. Funct. Regul. Tor Complexes Yeasts Mamm. Part B 2014 36 7 32 10.1016/b978-0-12-802215-3.00002-1 27102697

30. Kekulé A. Lehrbuch der Organischen Chemie Verlag von Ferdinand Enke Erlangen, Germany 1866 Volume 2

31. Newman A.A. Chemistry of Terpenes and Terpenoids Academic Press Cambridge, MA, USA 1972 449

32. Dionísio A.P. Molina G. de Carvalho D.S. dos Santos R. Bicas J. Pastore G. Natural flavourings from biotechnology for foods and beverages Natural Food Additives, Ingredients and Flavourings Elsevier Amsterdam, The Netherlands 2012 231 259

33. Leitereg T.J. Guadagni D.G. Harris J. Mon T.R. Teranishi R. Evidence for the Difference between the Odours of the Optical Isomers (+)- and (−)-Carvone Nat. Cell Biol. 1971 230 455 456 10.1038/230455a0 4932037

34. Sato T. Kobayakawa R. Kobayakawa K. Emura M. Itohara S. Kizumi M. Hamana H. Tsuboi A. Hirono J. Supersensitive detection and discrimination of enantiomers by dorsal olfactory receptors: Evidence for hierarchical odour coding Sci. Rep. 2015 5 14073 10.1038/srep14073 26361056 PMC4566093

35. Moss G.P. Basic terminology of stereochemistry (IUPAC Recommendations 1996) Pure Appl. Chem. 1996 68 2193 2222 10.1351/pac199668122193

36. Chastain D.E. Mody N. Majetich G. Method of preparing perillyl alcohol and perillyl acetate. United U.S. Patent US5994598 30 November 1999

37. Alonso-Gutierrez J. Chan R. Batth T.S. Adams P. Keasling J. Petzold C. Lee T.S. Metabolic engineering of Escherichia coli for limonene and perillyl alcohol production Metab. Eng. 2013 19 33 41 10.1016/j.ymben.2013.05.004 23727191

38. Ren Y. Liu S. Jin G. Yang X. Zhou Y.J. Microbial production of limonene and its derivatives: Achievements and perspectives Biotechnol. Adv. 2020 44 107628 10.1016/j.biotechadv.2020.107628 32882371

39. Soares-Castro P. Soares F. Santos P.M. Current Advances in the Bacterial Toolbox for the Biotechnological Production of Monoterpene-Based Aroma Compounds Molecules 2020 26 91 10.3390/molecules26010091 33379215 PMC7794910

40. Chen T. Levin D. Puppali S. Pharmaceutical compositions comprising monoterpenes. United U.S. Patent US9700524B2 11 July 2017

41. Crowell P.L. Lin S. Vedejs E. Gould M.N. Identification of metabolites of the antitumor agent d-limonene capable of inhibiting protein isoprenylation and cell growth Cancer Chemother. Pharmacol. 1992 31 205 212 10.1007/BF00685549 1464157

42. Crowell P.L. Ren Z. Lin S. Vedejs E. Gould M.N. Structure-activity relationships among monoterpene inhibitors of protein isoprenylation and cell proliferation Biochem. Pharmacol. 1994 47 1405 1415 10.1016/0006-2952(94)90341-7 8185648

43. Haag J.D. Gould M.N. Mammary carcinoma regression induced by perillyl alcohol, a hydroxylated analog of limonene Cancer Chemother. Pharmacol. 1994 34 477 483 10.1007/BF00685658 7923558

44. Elegbede J. Elson C. Qureshi A. Tanner M. Gould M. Inhibition of DMBA-induced mammary cancer by the monoterpene d-limonene Carcinogenesis 1984 5 661 664 10.1093/carcin/5.5.661 6426810

45. Elegbede J.A. Elson C.E. Qureshi A. Tanner M.A. Gould M.N. Regression of Rat Primary Mammary Tumors Following Dietary d-Limonene2 J. Natl. Cancer Inst. 1986 76 323 325 10.1093/jnci/76.2.323 3080636

46. Homburger F. Treger A. Boger E. Inhibition of Murine Subcutaneous and Intravenous Benzo(rst)pentaphene Carcinogenesis by Sweet Orange Oils and d-Limonene Oncology 1971 25 1 10 10.1159/000224548 5090417

47. Wattenberg L.W. Coccia J.B. Inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone carcinogenesis in mice by D-limonene and citrus fruit oils Carcinogenesis 1991 12 115 117 10.1093/carcin/12.1.115 1988170

48. Gelb M.H. Tamanoi F. Yokoyama K. Ghomashchi F. Esson K. Gould M.N. The inhibition of protein prenyltransferases by oxygenated metabolites of limonene and perillyl alcohol Cancer Lett. 1995 91 169 175 10.1016/0304-3835(95)03747-K 7767906

49. Crowell P. Chang R. Ren Z. Elson C. Gould M. Selective inhibition of isoprenylation of 21-26-kDa proteins by the anticarcinogen d-limonene and its metabolites J. Biol. Chem. 1991 266 17679 17685 10.1016/S0021-9258(19)47425-5 1894647

50. Da Fonseca C.O. Linden R. Futuro D. Gattass C.R. Quirico-Santos T. Ras pathway activation in gliomas: A strategic target for intranasal administration of perillyl alcohol Arch. Immunol. Ther. Exp. 2008 56 267 276 10.1007/s00005-008-0027-0 PMC2778682 18726148

51. Gould M.N. Prevention and therapy of mammary cancer by monoterpenes J. Cell. Biochem. 1995 59 139 144 10.1002/jcb.240590818 8538191

52. Holstein S.A. Hohl R.J. Monoterpene regulation of Ras and Ras-related protein expression J. Lipid Res. 2003 44 1209 1215 10.1194/jlr.M300057-JLR200 12671036

53. Rowinsky E.K. Windle J.J. Von Hoff D.D. Ras Protein Farnesyltransferase: A Strategic Target for Anticancer Therapeutic Development J. Clin. Oncol. 1999 17 3631 3652 10.1200/JCO.1999.17.11.3631 10550163

54. Ren Z. Elson C.E. Gould M.N. Inhibition of type I and type II geranylgeranyl-protein transferases by the monoterpene perillyl alcohol in NIH3T3 cells Biochem. Pharmacol. 1997 54 113 120 10.1016/S0006-2952(97)00151-2 9296357

55. A Ariazi E. Satomi Y. Ellis M.J. Haag J.D. Shi W. A Sattler C. Gould M.N. Activation of the transforming growth factor beta signaling pathway and induction of cytostasis and apoptosis in mammary carcinomas treated with the anticancer agent perillyl alcohol Cancer Res. 1999 59 1917 1928 10213501

56. Koyama M. Sowa Y. Hitomi T. Iizumi Y. Watanabe M. Taniguchi T. Ichikawa M. Sakai T. Perillyl alcohol causes g1 arrest through p15(ink4b) and p21(waf1/cip1) induction Oncol. Rep. 2013 29 779 784 10.3892/or.2012.2167 23233050

57. Wiseman D. Werner S.R. Crowell P.L. Cell Cycle Arrest by the Isoprenoids Perillyl Alcohol, Geraniol, and Farnesol Is Mediated by p21Cip1and p27Kip1in Human Pancreatic Adenocarcinoma Cells J. Pharmacol. Exp. Ther. 2006 320 1163 1170 10.1124/jpet.106.111666 17138864

58. Yuri T. Danbara N. Tsujita-Kyutoku M. Kiyozuka Y. Senzaki H. Shikata N. Kanzaki H. Tsubura A. Perillyl Alcohol Inhibits Human Breast Cancer Cell Growth in vitro and in vivo Breast Cancer Res. Treat. 2004 84 251 260 10.1023/B:BREA.0000019966.97011.4d 15026623

59. Satomi Y. Miyamoto S. Gould M.N. Induction of AP-1 activity by perillyl alcohol in breast cancer cells Carcinogenesis 1999 20 1957 1961 10.1093/carcin/20.10.1957 10506111

60. Sundin T. Peffley D.M. Gauthier D. Hentosh P. The isoprenoid perillyl alcohol inhibits telomerase activity in prostate cancer cells Biochimie 2012 94 2639 2648 10.1016/j.biochi.2012.07.028 22902867

61. Sundin T. Peffley D.M. Hentosh P. Disruption of an htert-mtor-raptor protein complex by a phytochemical perillyl alcohol and rapamycin Mol. Cell. Biochem. 2013 375 97 104 10.1007/s11010-012-1532-3 23283642

62. Peffley D.M. Sharma C. Hentosh P. Buechler R.D. Perillyl alcohol and genistein differentially regulate PKB/Akt and 4E-BP1 phosphorylation as well as eIF4E/eIF4G interactions in human tumor cells Arch. Biochem. Biophys. 2007 465 266 273 10.1016/j.abb.2007.05.022 17601486

63. Sundin T. Peffley D. Hentosh P. eIF4E-Overexpression imparts perillyl alcohol and rapamycin-mediated regulation of telomerase reverse transcriptase Exp. Cell Res. 2013 319 2103 2112 10.1016/j.yexcr.2013.05.029 23747720

64. Garcia D.G. Amorim L.M.F. Faria M.V.D.C. Freire A.S. Santelli R.E. Da Fonseca C.O. Quirico-Santos T. Burth P. The anticancer drug perillyl alcohol is a Na/K-ATPase inhibitor Mol. Cell. Biochem. 2010 345 29 34 10.1007/s11010-010-0556-9 20689980

65. Garcia D.G. de Castro-Faria-Neto H.C. da Silva C.I. Souza K.F.C.D.S.E. Gonçalves-De-Albuquerque C.F. Silva A.R. Amorim L.M.D.F.D. Freire A.S. Santelli R.E. Diniz L.P. Na/K-ATPase as a target for anticancer drugs: Studies with perillyl alcohol Mol. Cancer 2015 14 1 14 10.1186/s12943-015-0374-5 25976744 PMC4432499

66. Ma Y. Bian J. Zhang F. Inhibition of perillyl alcohol on cell invasion and migration depends on the Notch signaling pathway in hepatoma cells Mol. Cell. Biochem. 2015 411 307 315 10.1007/s11010-015-2593-x 26475687

67. Berchtold C.M. Chen K.S. Miyamoto S. Gould M.N. Perillyl alcohol inhibits a calcium-dependent constitutive nuclear factor-kappab pathway Cancer Res. 2005 65 8558 8566 10.1158/0008-5472.CAN-04-4072 16166337

68. Khan A.Q. Nafees S. Sultana S. Perillyl alcohol protects against ethanol induced acute liver injury in Wistar rats by inhibiting oxidative stress, NFκ-B activation and proinflammatory cytokine production Toxicology 2011 279 108 114 10.1016/j.tox.2010.09.017 20923693

69. Tabassum R. Vaibhav K. Shrivastava P. Khan A. Ahmed M.E. Ashafaq M. Khan M.B. Islam F. Safhi M.M. Islam F. Perillyl alcohol improves functional and histological outcomes against ischemia-reperfusion injury by attenuation of oxidative stress and repression of cox-2, nos-2 and nf-kappab in middle cerebral artery occlusion rats Eur. J. Pharmacol. 2015 747 190 199 10.1016/j.ejphar.2014.09.015 25240714

70. Ma J. Li J. Wang K.S. Mi C. Piao L.X. Xu G.H. Li X. Lee J.J. Jin X. Perillyl alcohol efficiently scavenges activity of cellular ROS and inhibits the translational expression of hypoxia-inducible factor-1α via mTOR/4E-BP1 signaling pathways Int. Immunopharmacol. 2016 39 1 9 10.1016/j.intimp.2016.06.034 27394002

71. Cho H.-Y. Wang W. Jhaveri N. Torres S. Tseng J. Leong M.N. Lee D.J. Goldkorn A. Xu T. Petasis N. Perillyl Alcohol for the Treatment of Temozolomide-Resistant Gliomas Mol. Cancer Ther. 2012 11 2462 2472 10.1158/1535-7163.MCT-12-0321 22933703

72. Nishitoh H. CHOP is a multifunctional transcription factor in the ER stress response J. Biochem. 2012 151 217 219 10.1093/jb/mvr143 22210905

73. Schönthal A.H. Endoplasmic Reticulum Stress: Its Role in Disease and Novel Prospects for Therapy Scientifica 2012 2012 1 26 10.6064/2012/857516 24278747 PMC3820435

74. Schönthal A.H. Pharmacological targeting of endoplasmic reticulum stress signaling in cancer Biochem. Pharmacol. 2013 85 653 666 10.1016/j.bcp.2012.09.012 23000916

75. Ripple G.H. Gould M.N. A Stewart J. Tutsch K.D. Arzoomanian R.Z. Alberti D. Feierabend C. Pomplun M. Wilding G. Bailey H.H. Phase I clinical trial of perillyl alcohol administered daily Clin. Cancer Res. 1998 4 1159 1164 9607573

76. Ripple G.H. Gould M.N. Arzoomanian R.Z. Alberti D. Feierabend C. Simon K. Binger K. Tutsch K.D. Pomplun M. Wahamaki A. Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day Clin. Cancer Res. 2000 6 390 396 10690515

77. Bailey H.H. Levy D. Harris L.S. Schink J.C. Foss F. Beatty P. Wadler S. A Phase II Trial of Daily Perillyl Alcohol in Patients with Advanced Ovarian Cancer: Eastern Cooperative Oncology Group Study E2E96 Gynecol. Oncol. 2002 85 464 468 10.1006/gyno.2002.6647 12051875

78. Liu G. Oettel K. Bailey H. Van Ummersen L. Tutsch K. Staab M.J. Horvath D. Alberti N. Arzoomanian R. Rezazadeh H. Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer Investig. New Drugs 2003 21 367 372 10.1023/A:1025437115182 14578686

79. Bailey H.H. Attia S. Love R.R. Fass T. Chappell R. Tutsch K. Harris L. Jumonville A. Hansen R. Shapiro G.R. Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer Cancer Chemother. Pharmacol. 2007 62 149 157 10.1007/s00280-007-0585-6 17885756

80. Matos J.M. Schmidt C.M. Thomas H.J. Cummings O.W. Wiebke E.A. Madura J.A. Patrick L.J. Crowell P. A Pilot Study of Perillyl Alcohol in Pancreatic Cancer J. Surg. Res. 2008 147 194 199 10.1016/j.jss.2008.02.005 18498869

81. Meadows S.M. Mulkerin D. Berlin J. Bailey H. Kolesar J. Warren D. Thomas J.P. Phase II Trial of Perillyl Alcohol in Patients with Metastatic Colorectal Cancer Int. J. Pancreatol. 2002 32 125 128 10.1385/IJGC:32:2-3:125 12794248

82. Durço A.O. Conceição L.S.R. de Souza D.S. Lima C.A. Quintans J.D.S.S. dos Santos M.R.V. Perillyl alcohol as a treatment for cancer: A systematic review Phytomedicine Plus 2021 1 100090 10.1016/j.phyplu.2021.100090

83. Erdő F. Bors L.A. Farkas D. Bajza Á. Gizurarson S. Evaluation of intranasal delivery route of drug administration for brain targeting Brain Res. Bull. 2018 143 155 170 10.1016/j.brainresbull.2018.10.009 30449731

84. Keller L.-A. Merkel O. Popp A. Intranasal drug delivery: Opportunities and toxicologic challenges during drug development Drug Deliv. Transl. Res. 2021 1 23 10.1007/s13346-020-00891-5 PMC7829061 33491126

85. Pardeshi C.V. Belgamwar V.S. Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: An excellent platform for brain targeting Epert Opin. Drug Deliv. 2013 10 957 972 10.1517/17425247.2013.790887 23586809

86. Dhas N. Yadav D. Singh A. Garkal A. Kudarha R. Bangar P. Savjani J. Pardeshi C.V. Garg N. Mehta T. Direct transport theory: From the nose to the brain Direct Nose-to-Brain Drug Delivery Pardeshi C.V. Souto E.B. Academic Press San Diego, CA, USA Cambridge, MA, USA Oxford, UK London, UK 2021 15 38

87. Khunt D. Misra M. Basic considerations of anatomical and physiological aspects of the nose and the brain Direct Nose-to-Brain Drug Delivery Pardeshi C.V. Souto E.B. Academic Press San Diego, CA, USA Cambridge, MA, USA Oxford, UK London, UK 2021 3 14

88. Laddha U.D. Tagalpallewar A.A. Physicochemical, biopharmaceutical, and practical considerations for efficient nose-to-brain drug delivery Direct Nose-to-Brain Drug Delivery Pardeshi C.V. Souto E.B. Academic Press San Diego, CA, USA Cambridge, MA, USA Oxford, UK London, UK 2021 39 56

89. Gänger S. Schindowski K. Tailoring Formulations for Intranasal Nose-to-Brain Delivery: A Review on Architecture, Physico-Chemical Characteristics and Mucociliary Clearance of the Nasal Olfactory Mucosa Pharmaceutics 2018 10 116 10.3390/pharmaceutics10030116 30081536 PMC6161189

90. Crowe T. Greenlee M.H.W. Kanthasamy A. Hsu W.H. Mechanism of intranasal drug delivery directly to the brain Life Sci. 2018 195 44 52 10.1016/j.lfs.2017.12.025 29277310

91. Djupesland P.G. Messina J.C. A Mahmoud R. The nasal approach to delivering treatment for brain diseases: An anatomic, physiologic, and delivery technology overview Ther. Deliv. 2014 5 709 733 10.4155/tde.14.41 25090283

92. Chen T.C. Da Fonseca C.O. Schönthal A.H. Preclinical development and clinical use of perillyl alcohol for chemoprevention and cancer therapy Am. J. Cancer Res. 2015 5 1580 1593 26175929 PMC4497427

93. Da Fonseca C.O. Masini M. Futuro D. Caetano R. Gattass C.R. Quirico-Santos T. Anaplastic oligodendroglioma responding favorably to intranasal delivery of perillyl alcohol: A case report and literature review Surg. Neurol. 2006 66 611 615 10.1016/j.surneu.2006.02.034 17145324

94. da Fonseca C.O. Schwartsmann G. Fischer J. Nagel J. Futuro D. Quirico-Santos T. Gattass C.R. Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas Surg. Neurol. 2008 70 259 266 10.1016/j.surneu.2007.07.040 18295834

95. Da Fonseca C.O. Simão M. Lins I.R. Caetano R.O. Futuro D. Quirico-Santos T. Efficacy of monoterpene perillyl alcohol upon survival rate of patients with recurrent glioblastoma J. Cancer Res. Clin. Oncol. 2010 137 287 293 10.1007/s00432-010-0873-0 20401670 PMC11828245

96. Da Fonseca C.O. Teixeira R.M. Silva J.C.T. Fischer J.D.S.D.G. Meirelles O.C. Landeiro J.A. Quirico-Santos T. Long-term outcome in patients with recurrent malignant glioma treated with Perillyl alcohol inhalation Anticancer Res. 2013 33 5625 5631 24324108

97. Schönthal A.H. Peereboom D.M. Wagle N. Lai R. Mathew A.J. Hurth K.M. Simmon V.F. Howard S.P. Taylor L.P. Chow F. Phase I trial of intranasal NEO100, highly purified perillyl alcohol, in adult patients with recurrent glioblastoma Neuro-Oncol. Adv. 2021 3 vdab005 10.1093/noajnl/vdab005 PMC7879254 33604574

98. National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 Available online: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_50 (accessed on 15 July 2021)

99. Barker F.G. II Chang S.M. Gutin P.H. Malec M.K. McDermott M.W. Prados M.D. Wilson C.B. Survival and functional status after resection of recurrent glioblastoma multiforme Neurosurgery 1998 42 709 720 discussion 720–703 10.1097/00006123-199804000-00013 9574634

100. Batchelor T.T. Mulholland P. Neyns B. Nabors L.B. Campone M. Wick A. Mason W. Mikkelsen T. Phuphanich S. Ashby L.S. Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma J. Clin. Oncol. 2013 31 3212 3218 10.1200/JCO.2012.47.2464 23940216 PMC4021043

101. Brandes A.A. Finocchiaro G. Zagonel V. Reni M. Caserta C. Fabi A. Clavarezza M. Maiello E. Eoli M. Lombardi G. AVAREG: A phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma Neuro-Oncology 2016 18 1304 1312 10.1093/neuonc/now035 26951379 PMC4998997

102. Desjardins A. Herndon J.E. II McSherry F. Ravelo A. Lipp E.S. Healy P. Peters K.B. Sampson J.H. Randazzo D. Sommer N. Single-institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice Health Sci. Rep. 2019 2 e114 10.1002/hsr2.114 31049419 PMC6482327

103. Ghiaseddin A. Peters K.B. Use of bevacizumab in recurrent glioblastoma CNS Oncol. 2015 4 157 169 10.2217/cns.15.8 25906439 PMC6088330

104. Weller M. Le Rhun E. How did lomustine become standard of care in recurrent glioblastoma? Cancer Treat. Rev. 2020 87 102029 10.1016/j.ctrv.2020.102029 32408220

105. Da Fonseca C.O. Silva J.T. Lins I.R. Simão M. Arnobio A. Futuro D. Quirico-Santos T. Correlation of tumor topography and peritumoral edema of recurrent malignant gliomas with therapeutic response to intranasal administration of perillyl alcohol Investig. New Drugs 2009 27 557 564 10.1007/s10637-008-9215-3 19139816

106. Faria G.M. Soares I.D.P. D’Alincourt Salazar M. Amorim M.R. Pessoa B.L. da Fonseca C.O. Quirico-Santos T. Intranasal perillyl alcohol therapy improves survival of patients with recurrent glioblastoma harboring mutant variant for mthfr rs1801133 polymorphism BMC Cancer 2020 20 294 10.1186/s12885-020-06802-8 32264844 PMC7137265

107. Waitkus M.S. Diplas B.H. Yan H. Biological Role and Therapeutic Potential of IDH Mutations in Cancer Cancer Cell 2018 34 186 195 10.1016/j.ccell.2018.04.011 29805076 PMC6092238

108. Yang H. Ye D. Guan K.-L. Xiong Y. IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives Clin. Cancer Res. 2012 18 5562 5571 10.1158/1078-0432.CCR-12-1773 23071358 PMC3897211

109. Huang L.E. Friend or foe—IDH1 mutations in glioma 10 years on Carcinogenesis 2019 40 1299 1307 10.1093/carcin/bgz134 31504231 PMC6875900

110. Tabei Y. Kobayashi K. Saito K. Shimizu S. Suzuki K. Sasaki N. Shiokawa Y. Nagane M. Survival in patients with glioblastoma at a first progression does not correlate with isocitrate dehydrogenase (IDH)1 gene mutation status Jpn. J. Clin. Oncol. 2021 51 45 53 10.1093/jjco/hyaa162 32888020 PMC7767982

111. Da Fonseca C. Soares I.P. Clemençon D.S. Rochlin S. Cardeman L. Quirico-Santos T. Perillyl alcohol inhalation concomitant with oral temozolomide halts progression of recurrent inoperable glioblastoma: A case report J. Histol. Histopathol. 2015 2 12 10.7243/2055-091X-2-12

112. Santos J.G. Da Cruz W.M.S. Schönthal A.H. Salazar M.D. Fontes C.A.P. Quirico-Santos T. Da Fonseca C.O. Efficacy of a ketogenic diet with concomitant intranasal perillyl alcohol as a novel strategy for the therapy of recurrent glioblastoma Oncol. Lett. 2017 15 1263 1270 10.3892/ol.2017.7362 29391903 PMC5769394

113. Santos J.G. Faria G. Cruz W.D.C.S.D. Fontes C.A. Schönthal A.H. Quirico-Santos T. Da Fonseca C.O. Adjuvant effect of low-carbohydrate diet on outcomes of patients with recurrent glioblastoma under intranasal perillyl alcohol therapy Surg. Neurol. Int. 2020 11 389 10.25259/SNI_445_2020 33282452 PMC7710475

114. Zhang Z. Chen H. Chan K.K. Budd T. Ganapathi R. Gas chromatographic–mass spectrometric analysis of perillyl alcohol and metabolites in plasma J. Chromatogr. B Biomed. Sci. Appl. 1999 728 85 95 10.1016/S0378-4347(99)00065-1 10379660

115. Santos J.D.S. Diedrich C. Machado C.S. da Fonseca C.O. Khalil N.M. Mainardes R.M. Intranasal administration of perillyl alcohol–loaded nanoemulsion and pharmacokinetic study of its metabolite perillic acid in plasma and brain of rats using ultra-performance liquid chromatography/tandem mass spectrometry Biomed. Chromatogr. 2021 35 e5037 10.1002/bmc.5037 33238042

116. De Lima D.C. Rodrigues S.V. Boaventura G.T. Cho H. Chen T.C. Schönthal A.H. Da Fonseca C.O. Simultaneous measurement of perillyl alcohol and its metabolite perillic acid in plasma and lung after inhalational administration in Wistar rats Drug Test. Anal. 2019 12 268 279 10.1002/dta.2722 31800149

117. Marin A.A. Murillo O. Sussmann R.A. Ortolan L.S. Battagello D.S. Quirino T.D.C. Bittencourt J.C. Epiphanio S. Katzin A.M. Carvalho L.J.M. Perillyl Alcohol Reduces Parasite Sequestration and Cerebrovascular Dysfunction during Experimental Cerebral Malaria Antimicrob. Agents Chemother. 2021 65 10.1128/AAC.00004-21 33649109 PMC8092904

118. Nehra G. Andrews S. Rettig J. Gould M.N. Haag J.D. Howard S.P. Thorne R.G. Intranasal administration of the chemotherapeutic perillyl alcohol results in selective delivery to the cerebrospinal fluid in rats Sci. Rep. 2021 11 1 11 10.1038/s41598-021-85293-4 33737566 PMC7973779

119. Eftekhari R.B. Maghsoudnia N. Samimi S. Zamzami A. Dorkoosh F.A. Co-Delivery Nanosystems for Cancer Treatment: A Review Pharm. Nanotechnol. 2019 7 90 112 10.2174/2211738507666190321112237 30907329

120. Guo P. He Y. Xu T. Pi C. Jiang Q. Wei Y. Zhao L. Co-delivery system of chemotherapy drugs and active ingredients from natural plants: A brief overview of preclinical research for cancer treatment Expert Opin. Drug Deliv. 2020 17 665 675 10.1080/17425247.2020.1739647 32149539

121. Ferreira N.N. Junior E.D.O. Granja S. Boni F.I. Ferreira L.M. Cury B.S. Santos L.C. Reis R.M. Lima E.M. Baltazar F. Nose-to-brain co-delivery of drugs for glioblastoma treatment using nanostructured system Int. J. Pharm. 2021 603 120714 10.1016/j.ijpharm.2021.120714 34015380

122. Mignani S. Shi X. Karpus A. Majoral J.-P. Non-invasive intranasal administration route directly to the brain using dendrimer nanoplatforms: An opportunity to develop new CNS drugs Eur. J. Med. Chem. 2021 209 112905 10.1016/j.ejmech.2020.112905 33069435 PMC7548078

123. Wang W. Swenson S. Cho H.-Y. Hofman F.M. Schönthal A.H. Chen T.C. Efficient brain targeting and therapeutic intracranial activity of bortezomib through intranasal co-delivery with NEO100 in rodent glioblastoma models J. Neurosurg. 2020 132 959 967 10.3171/2018.11.JNS181161 30875688

124. Scott K. Hayden P.J. Will A. Wheatley K. Coyne I. Bortezomib for the treatment of multiple myeloma Cochrane Database Syst. Rev. 2016 4 CD010816 10.1002/14651858.CD010816.pub2 27096326 PMC10387344

125. Hemeryck A. Geerts R. Monbaliu J. Hassler S. Verhaeghe T. Diels L. Verluyten W. Van Beijsterveldt L. Mamidi R.N.V.S. Janssen C. Tissue distribution and depletion kinetics of bortezomib and bortezomib-related radioactivity in male rats after single and repeated intravenous injection of 14C-bortezomib Cancer Chemother. Pharmacol. 2007 60 777 787 10.1007/s00280-007-0424-9 17285316

126. Pinel S. Labussiere M. Delfortrie S. Plenat F. Chastagner P. Proteasome inhibition by bortezomib does not translate into efficacy on two malignant glioma xenografts Oncol. Rep. 1994 20 1283 1287 10.3892/or_00000142 18949434

127. Wang W. Cho H.-Y. Rosenstein-Sisson R. Ramos N.I.M. Price R. Hurth K. Schönthal A.H. Hofman F.M. Chen T.C. Intratumoral delivery of bortezomib: Impact on survival in an intracranial glioma tumor model J. Neurosurg. 2018 128 695 700 10.3171/2016.11.JNS161212 28409734

128. Friday B.B. Anderson S.K. Buckner J. Yu C. Giannini C. Geoffroy F. Schwerkoske J. Mazurczak M. Gross H. Pajon E. Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: A north central cancer treatment group study Neuro-Oncology 2011 14 215 221 10.1093/neuonc/nor198 22090453 PMC3266383

129. Odia Y. Kreisl T.N. Aregawi D. Innis E.K. Fine H.A. A phase II trial of tamoxifen and bortezomib in patients with recurrent malignant gliomas J. Neuro-Oncol. 2015 125 191 195 10.1007/s11060-015-1894-y 26285768

130. Raizer J.J. Chandler J.P. Ferrarese R. Grimm S.A. Levy R.M. Muro K. Rosenow J. Helenowski I. Rademaker A. Paton M. A phase II trial evaluating the effects and intra-tumoral penetration of bortezomib in patients with recurrent malignant gliomas J. Neuro-Oncol. 2016 129 139 146 10.1007/s11060-016-2156-3 27300524

131. Bota D.A. Alexandru D. Keir S.T. Bigner D. Vredenburgh J. Friedman H.S. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells’ VEGF production and angiogenesis J. Neurosurg. 2013 119 1415 1423 10.3171/2013.7.JNS1323 24093630 PMC4550014

132. Kardosh A. Golden E.B. Pyrko P. Uddin J. Hofman F.M. Chen T.C. Louie S.G. Petasis N. Schönthal A.H. Aggravated Endoplasmic Reticulum Stress as a Basis for Enhanced Glioblastoma Cell Killing by Bortezomib in Combination with Celecoxib or Its Non-Coxib Analogue, 2,5-Dimethyl-Celecoxib Cancer Res. 2008 68 843 851 10.1158/0008-5472.CAN-07-5555 18245486

133. Styczynski J. Olszewska-Slonina D. Kolodziej B. Napieraj M. Wysocki M. Activity of bortezomib in glioblastoma Anticancer. Res. 2007 26 4499 4503 17201170

134. Joshi S. Ergin A. Wang M. Reif R. Zhang J. Bruce J.N. Bigio I.J. Inconsistent blood brain barrier disruption by intraarterial mannitol in rabbits: Implications for chemotherapy J. Neuro-Oncol. 2010 104 11 19 10.1007/s11060-010-0466-4 21153681 PMC4013427

135. Joshi S. Meyers P.M. Ornstein E. Intracarotid delivery of drugs: The potential and the pitfalls Anesthesiology 2008 109 543 564 10.1097/ALN.0b013e318182c81b 18719453 PMC3999414

136. Lundqvist H. Rosander K. Lomanov M. Lukjashin V. Shimchuk G. Zolotov V. Minakova E. Permeability of the Blood-Brain Barrier in the Rat after Local Proton Irradiation Acta Radiol. Oncol. 1982 21 267 271 10.3109/02841868209134015 6293269

137. A Peña L. Fuks Z. Kolesnick R.N. Radiation-induced apoptosis of endothelial cells in the murine central nervous system: Protection by fibroblast growth factor and sphingomyelinase deficiency Cancer Res. 2000 60 321 327 10667583

138. Sprowls S.A. Arsiwala T. Bumgarner J. Shah N. Lateef S.S. Kielkowski B.N. Lockman P.R. Improving CNS Delivery to Brain Metastases by Blood–Tumor Barrier Disruption Trends Cancer 2019 5 495 505 10.1016/j.trecan.2019.06.003 31421906 PMC6703178

139. Dasgupta A. Liu M. Ojha T. Storm G. Kiessling F. Lammers T. Ultrasound-mediated drug delivery to the brain: Principles, progress and prospects Drug Discov. Today Technol. 2016 20 41 48 10.1016/j.ddtec.2016.07.007 27986222 PMC5166975

140. Abrahao A. Meng Y. Llinas M. Huang Y. Hamani C. Mainprize T. Aubert I. Heyn C. Black S.E. Hynynen K. First-in-human trial of blood–brain barrier opening in amyotrophic lateral sclerosis using MR-guided focused ultrasound Nat. Commun. 2019 10 1 9 10.1038/s41467-019-12426-9 31558719 PMC6763482

141. Carpentier A. Canney M. Vignot A. Reina V. Beccaria K. Horodyckid C. Karachi C. Leclercq D. Lafon C. Chapelon J.-Y. Clinical trial of blood-brain barrier disruption by pulsed ultrasound Sci. Transl. Med. 2016 8 343re2 10.1126/scitranslmed.aaf6086 27306666

142. Arvanitis C.D. Askoxylakis V. Guo Y. Datta M. Kloepper J. Ferraro G.B. Bernabeu M.O. Fukumura D. McDannold N. Jain R.K. Mechanisms of enhanced drug delivery in brain metastases with focused ultrasound-induced blood–tumor barrier disruption Proc. Natl. Acad. Sci. USA 2018 115 E8717 E8726 10.1073/pnas.1807105115 30150398 PMC6140479

143. Wang W. He H. Marín-Ramos N.I. Zeng S. Swenson S. Cho H.-Y. Fu J. Beringer P.M. Neman J. Chen L. Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by neo100 in mouse models of brain-metastatic breast cancer Neuro Oncol. 2021 e-pub ahead of print 10.1093/neuonc/noab204 33659980 PMC8485439

144. Wang W. I Marín-Ramos N. He H. Zeng S. Cho H.-Y. Swenson S.D. Zheng L. Epstein A.L. Schönthal A.H. Hofman F.M. NEO100 enables brain delivery of blood–brain barrier impermeable therapeutics Neuro-Oncology 2021 23 63 75 10.1093/neuonc/noaa206 32877532 PMC7850137

145. Aouad-Maroun M. Raphael C.K. Sayyid S.K. Farah F. Akl E.A. Ultrasound-guided arterial cannulation for paediatrics Cochrane Database Syst. Rev. 2016 9 CD011364 10.1002/14651858.CD011364.pub2 27627458 PMC6353047

146. Hou X.-T. Sun Y.-Q. Zhang H.-J. Zheng S.-H. Liu Y.-Y. Wang J.-G. Femoral Artery Cannulation in Stanford Type a Aortic Dissection Operations Asian Cardiovasc. Thorac. Ann. 2006 14 35 37 10.1177/021849230601400109 16432116

147. Saadat S. Schultheis M. Azzolini A. Romero J. Dombrovskiy V. Odroniec K. Scholz P. Lemaire A. Batsides G. Lee L. Femoral cannulation: A safe vascular access option for cardiopulmonary bypass in minimally invasive cardiac surgery Perfusion 2016 31 131 134 10.1177/0267659115588631 26034193

148. Bangalore S. Bhatt D.L. Femoral Arterial Access and Closure Circulation 2011 124 e147 e156 10.1161/circulationaha.111.032235 21810667

149. Scheer B.V. Perel A. Pfeiffer U.J. Clinical review: Complications and risk factors of peripheral arterial catheters used for haemodynamic monitoring in anaesthesia and intensive care medicine Crit. Care 2002 6 199 204 10.1186/cc1489 12133178 PMC137445

150. Fusco D.S. Shaw R.K. Tranquilli M. Kopf G.S. Elefteriades J.A. Femoral Cannulation is Safe for Type A Dissection Repair Ann. Thorac. Surg. 2004 78 1285 1289 10.1016/j.athoracsur.2004.04.072 15464486

151. Sattenberg R.J. Meckler J. Saver J.L. Gobin Y.P. Liebeskind D.S. Cerebral angiography Stroke: Pathophysiology, Diagnosis, and Management 6th ed. Grotta J.C. Elsevier Inc. Amsterdam, The Netherlands 2016 790 805

152. Gantt R.W. Peltier-Pain P. Thorson J.S. Enzymatic methods for glyco(diversification/randomization) of drugs and small molecules Nat. Prod. Rep. 2011 28 1811 1853 10.1039/c1np00045d 21901218

153. Fujita T. Ohira K. Miyatake K. Nakano Y. Nakayama M. Inhibitory Effect of Perillosides A and C, and Related Monoterpene Glucosides on Aldose Reductase and Their Structure-Activity Relationships Chem. Pharm. Bull. 1995 43 920 926 10.1248/cpb.43.920 7641310

154. Arafa H.M. Possible contribution of beta-glycosidases and caspases in the cytotoxicity of novel glycoconjugates in colon cancer cells Invest New Drugs 2010 28 306 317 10.1007/s10637-009-9248-2 19415182

155. Nandurkar N.S. Zhang J. Ye Q. Ponomareva L.V. She Q.-B. Thorson J.S. The Identification of Perillyl Alcohol Glycosides with Improved Antiproliferative Activity J. Med. Chem. 2014 57 7478 7484 10.1021/jm500870u 25121720 PMC4161159

156. Xanthakis E. Magkouta S. Loutrari H. Stamatis H. Roussos C. Kolisis F.N. Enzymatic synthesis of perillyl alcohol derivatives and investigation of their antiproliferative activity Biocatal. Biotransformation 2009 27 170 178 10.1080/10242420902811089

157. Said B. Montenegro I. Valenzuela M. Olguín Y. Caro N. Werner E. Godoy P. Villena J. Madrid A. Synthesis and Antiproliferative Activity of New Cyclodiprenyl Phenols against Select Cancer Cell Lines Molecules 2018 23 2323 10.3390/molecules23092323 30213053 PMC6225466

158. Rezende A.A. Santos R.S. Andrade L.N. Amaral R.G. Pereira M.M. Bani C. Chen M. Priefer R. da Silva C.F. de Albuquerque Junior R.L.C. Anti-tumor efficiency of perillylalcohol/beta-cyclodextrin inclusion complexes in a sarcoma s180-induced mice model Pharmaceutics 2021 13 245 10.3390/pharmaceutics13020245 33578857 PMC7916601

159. Da Silva C.E.H. Gosmann G. de Andrade S.F. Limonene and perillyl alcohol derivatives: Synthesis and anticancer activity Mini Rev. Med. Chem. 2021 21 1813 1829 10.2174/1389557521666210212150504 33583370

160. Zielińska-Błajet M. Pietrusiak P. Feder-Kubis J. Selected Monocyclic Monoterpenes and Their Derivatives as Effective Anticancer Therapeutic Agents Int. J. Mol. Sci. 2021 22 4763 10.3390/ijms22094763 33946245 PMC8124601

161. Hopkins A.L. Network pharmacology: The next paradigm in drug discovery Nat. Chem. Biol. 2008 4 682 690 10.1038/nchembio.118 18936753

162. Szumilak M. Wiktorowska-Owczarek A. Stanczak A. Hybrid Drugs—A Strategy for Overcoming Anticancer Drug Resistance? Molecules 2021 26 2601 10.3390/molecules26092601 33946916 PMC8124695

163. Vendrusculo V. de Souza V.P. LA M.F. MG M.D.O. Banzato T.P. Monteiro P.A. Pilli R.A. de Carvalho J.E. Russowsky D. Synthesis of novel perillyl-dihydropyrimidinone hybrids designed for antiproliferative activity Medchemcomm 2018 9 1553 1564 10.1039/C8MD00270C 30288229 PMC6151448

164. Mohammadi B. Behbahani F.K. Recent developments in the synthesis and applications of dihydropyrimidin-2(1H)-ones and thiones Mol. Divers. 2018 22 405 446 10.1007/s11030-017-9806-z 29349521

165. Chen T.C. Cho H.-Y. Wang W. Barath M. Sharma N. Hofman F.M. Schönthal A.H. A Novel Temozolomide–Perillyl Alcohol Conjugate Exhibits Superior Activity against Breast Cancer Cells In Vitro and Intracranial Triple-Negative Tumor Growth In Vivo Mol. Cancer Ther. 2014 13 1181 1193 10.1158/1535-7163.MCT-13-0882 24623736

166. Chen T.C. Cho H.-Y. Wang W. Wetzel S.J. Singh A. Nguyen J. Hofman F.M. Schönthal A.H. Chemotherapeutic effect of a novel temozolomide analog on nasopharyngeal carcinoma in vitro and in vivo J. Biomed. Sci. 2015 22 71 80 10.1186/s12929-015-0175-6 26282951 PMC4539921

167. Schönthal A. Swenson S. Minea R. Kim H. Cho H. Mohseni N. Kim Y.-M. Chen T. Potentially Curative Therapeutic Activity of NEO212, a Perillyl Alcohol-Temozolomide Conjugate, in Preclinical Cytarabine-Resistant Models of Acute Myeloid Leukemia Cancers 2021 13 3385 10.3390/cancers13143385 34298603 PMC8305595

168. Chen T.C. Cho H.-Y. Wang W. Nguyen J. Jhaveri N. Rosenstein-Sisson R. Hofman F.M. Schönthal A.H. A novel temozolomide analog, NEO212, with enhanced activity against MGMT-positive melanoma in vitro and in vivo Cancer Lett. 2015 358 144 151 10.1016/j.canlet.2014.12.021 25524552

169. Cho H.-Y. Swenson S. Thein T.Z. Wang W. Wijeratne N.R. I Marín-Ramos N. E Katz J. Hofman F.M. Schönthal A.H. Chen T.C. Pharmacokinetic properties of the temozolomide perillyl alcohol conjugate (NEO212) in mice Neuro-Oncol. Adv. 2020 2 vdaa160 10.1093/noajnl/vdaa160 33392507 PMC7764505

170. Cho H.-Y. Wang W. Jhaveri N. Lee D.J. Sharma N. Dubeau L. Schönthal A.H. Hofman F.M. Chen T.C. NEO212, Temozolomide Conjugated to Perillyl Alcohol, Is a Novel Drug for Effective Treatment of a Broad Range of Temozolomide-Resistant Gliomas Mol. Cancer Ther. 2014 13 2004 2017 10.1158/1535-7163.MCT-13-0964 24994771

171. Jhaveri N. Agasse F. Armstrong D. Peng L. Commins D. Wang W. Rosenstein-Sisson R. Vaikari V.P. Santiago S.V. Santos T. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells Cancer Lett. 2016 371 240 250 10.1016/j.canlet.2015.11.040 26683773

172. Di Francia R. Crisci S. De Monaco A. Cafiero C. Re A. Iaccarino G. De Filippi R. Frigeri F. Corazzelli G. Micera A. Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers Cancers 2021 13 966 10.3390/cancers13050966 33669053 PMC7956511

173. Zhang J. Stevens M.F. Bradshaw T.D. Temozolomide: Mechanisms of action, repair and resistance Curr. Mol. Pharmacol. 2012 5 102 114 10.2174/1874467211205010102 22122467

174. Zhu J. Mix E. Winblad B. The Antidepressant and Antiinflammatory Effects of Rolipram in the Central Nervous System CNS Drug Rev. 2001 7 387 398 10.1111/j.1527-3458.2001.tb00206.x 11830756 PMC6741679

175. Chen T.C. Wadsten P. Su S. Rawlinson N. Hofman F.M. Hill C.K. Schonthal A.H. The type iv phosphodiesterase inhibitor rolipram induces expression of the cell cycle inhibitors p21(cip1) and p27(kip1), resulting in growth inhibition, increased differentiation, and subsequent apoptosis of malignant a-172 glioma cells Cancer Biol. Ther. 2002 1 268 276 10.4161/cbt.80 12432276

176. Goldhoff P. Warrington N.M. Limbrick D.D. Jr. Hope A. Woerner B.M. Jackson E. Perry A. Piwnica-Worms D. Rubin J.B. Targeted Inhibition of Cyclic AMP Phosphodiesterase-4 Promotes Brain Tumor Regression Clin. Cancer Res. 2008 14 7717 7725 10.1158/1078-0432.CCR-08-0827 19047098 PMC2615415

177. Cho H.-Y. Thein T.Z. Wang W. Swenson S.D. Fayngor R.A. Ou M. Marín-Ramos N.I. Schönthal A.H. Hofman F.M. Chen T.C. The Rolipram–Perillyl Alcohol Conjugate (NEO214) Is A Mediator of Cell Death through the Death Receptor Pathway Mol. Cancer Ther. 2019 18 517 530 10.1158/1535-7163.MCT-18-0465 30647121

178. Chen T.C. Chan N. Labib S. Yu J. Cho H.-Y. Hofman F.M. Schönthal A.H. Induction of Pro-Apoptotic Endoplasmic Reticulum Stress in Multiple Myeloma Cells by NEO214, Perillyl Alcohol Conjugated to Rolipram Int. J. Mol. Sci. 2018 19 277 10.3390/ijms19010277 29342125 PMC5796223

179. Fan T. Sun G. Sun X. Zhao L. Zhong R. Peng Y. Tumor Energy Metabolism and Potential of 3-Bromopyruvate as an Inhibitor of Aerobic Glycolysis: Implications in Tumor Treatment Cancers 2019 11 317 10.3390/cancers11030317 30845728 PMC6468516

180. Birsoy K. Wang T. Possemato R. Yilmaz O.H. E Koch C. Chen W. Hutchins A.W. Gultekin Y. Peterson T.R. Carette J. MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors Nat. Genet. 2013 45 104 108 10.1038/ng.2471 23202129 PMC3530647

181. Chen T.C. Yu J. Nigjeh E.N. Wang W. Myint P.T. Zandi E. Hofman F.M. Schönthal A.H. A perillyl alcohol-conjugated analog of 3-bromopyruvate without cellular uptake dependency on monocarboxylate transporter 1 and with activity in 3-BP-resistant tumor cells Cancer Lett. 2017 400 161 174 10.1016/j.canlet.2017.04.015 28450161

182. Göttlicher M. Valproic acid: An old drug newly discovered as inhibitor of histone deacetylases Ann. Hematol. 2004 83 (Suppl. 1) S91 S92 15124690 10.1007/s00277-004-0850-2

183. Martirosian V. Deshpande K. Zhou H. Shen K. Smith K. Northcott P. Lin M. Stepanosyan V. Das D. Remsik J. Medulloblastoma uses GABA transaminase to survive in the cerebrospinal fluid microenvironment and promote leptomeningeal dissemination Cell Rep. 2021 36 109475 10.1016/j.celrep.2021.109475 34320362 PMC12776182

184. Haque T. Talukder M.U. Chemical Enhancer: A Simplistic Way to Modulate Barrier Function of the Stratum Corneum Adv. Pharm. Bull. 2018 8 169 179 10.15171/apb.2018.021 30023318 PMC6046426

185. Li B.S. Cary J.H. Maibach H.I. Stratum corneum substantivity: Drug development implications Arch. Dermatol. Res. 2018 310 537 549 10.1007/s00403-018-1841-9 29752541

186. Kováčik A. Kopečná M. Vávrová K. Permeation enhancers in transdermal drug delivery: Benefits and limitations Expert Opin. Drug Deliv. 2020 17 145 155 10.1080/17425247.2020.1713087 31910342

187. Lopes L.B. Garcia M.T.J. Bentley M.V.L. Chemical penetration enhancers Ther. Deliv. 2015 6 1053 1061 10.4155/tde.15.61 26458111

188. Chen J. Jiang Q.-D. Chai Y.-P. Zhang H. Peng P. Yang X.-X. Natural Terpenes as Penetration Enhancers for Transdermal Drug Delivery Molecules 2016 21 1709 10.3390/molecules21121709 27973428 PMC6273457

189. Kopečná M. Macháček M. Nováčková A. Paraskevopoulos G. Roh J. Vávrová K. Esters of terpene alcohols as highly potent, reversible, and low toxic skin penetration enhancers Sci. Rep. 2019 9 1 12 10.1038/s41598-019-51226-5 31601936 PMC6787078

190. Lluria-Prevatt M. Morreale J. Gregus J. Alberts D.S. Kaper F. Giaccia A. Powell M.B. Effects of perillyl alcohol on melanoma in the TPras mouse model Cancer Epidemiol. Biomark. Prev. 2002 11 573 579 12050099

191. Chaudhary S.C. Alam M.S. Siddiqui M. Athar M. Perillyl alcohol attenuates Ras-ERK signaling to inhibit murine skin inflammation and tumorigenesis Chem.-Biol. Interact. 2009 179 145 153 10.1016/j.cbi.2008.12.016 19161993

192. Barthelman M. Chen W. Gensler H.L. Huang C. Dong Z. Bowden G.T. Inhibitory effects of perillyl alcohol on UVB-induced murine skin cancer and AP-1 transactivation Cancer Res. 1998 58 711 716 9485025

193. Gupta A. Myrdal P.B. Development of a perillyl alcohol topical cream formulation Int. J. Pharm. 2004 269 373 383 10.1016/j.ijpharm.2003.09.026 14706249

194. Stratton S.P. Saboda K.L. Myrdal P.B. Gupta A. McKenzie N.E. Brooks C. Salasche S.J. Warneke J.A. Ranger-Moore J. Bozzo P.D. Phase 1 Study of Topical Perillyl Alcohol Cream for Chemoprevention of Skin Cancer Nutr. Cancer 2008 60 325 330 10.1080/01635580701840391 18444166

195. Stratton S.P. Alberts D.S. Einspahr J.G. Sagerman P.M. Warneke J.A. Curiel-Lewandrowski C. Myrdal P.B. Karlage K.L. Nickoloff B.J. Brooks C. A Phase 2a Study of Topical Perillyl Alcohol Cream for Chemoprevention of Skin Cancer Cancer Prev. Res. 2010 3 160 169 10.1158/1940-6207.CAPR-09-0183 PMC3270887 20103724

196. D’Alessio P. Mirshahi M. Bisson J.-F. Bene M. Skin Repair Properties of d-Limonene and Perillyl Alcohol in Murine Models Anti-Inflamm. Anti-Allergy Agents Med. Chem. 2014 13 29 35 10.2174/18715230113126660021 24160248

197. Araujo-Filho H.G. Pereira E.W.M. Heimfarth L. Souza Monteiro B. Santos Passos F.R. Siqueira-Lima P. Gandhi S.R. Viana Dos Santos M.R. Guedes da Silva Almeida J.R. Picot L. Limonene, a food additive, and its active metabolite perillyl alcohol improve regeneration and attenuate neuropathic pain after peripheral nerve injury: Evidence for il-1beta, tnf-alpha, gap, ngf and erk involvement Int. Immunopharmacol. 2020 86 106766 10.1016/j.intimp.2020.106766 32652504

198. Erickson C. Miller S.J. Treatment options in melanoma in situ: Topical and radiation therapy, excision and Mohs surgery Int. J. Dermatol. 2010 49 482 491 10.1111/j.1365-4632.2010.04423.x 20534080

199. Van Zyl L. du Preez J. Gerber M. du Plessis J. Viljoen J. Essential Fatty Acids as Transdermal Penetration Enhancers J. Pharm. Sci. 2016 105 188 193 10.1016/j.xphs.2015.11.032 26852854

200. Viljoen J. Cowley A. du Preez J. Gerber M. Du Plessis J. Penetration enhancing effects of selected natural oils utilized in topical dosage forms Drug Dev. Ind. Pharm. 2015 41 2045 2054 10.3109/03639045.2015.1047847 26161938

201. Swenson S. Silva-Hirschberg C. Wang W. Singh A. Hofman F.M. Chen K.L. Schönthal A.H. Chen T.C. NEO412: A temozolomide analog with transdermal activity in melanoma in vitro and in vivo Oncotarget 2018 9 37026 37041 10.18632/oncotarget.26443 30651933 PMC6319336

Figures and Schemes